WO2020202148A1 - Microbial consortium and uses thereof - Google Patents
Microbial consortium and uses thereof Download PDFInfo
- Publication number
- WO2020202148A1 WO2020202148A1 PCT/IL2020/050389 IL2020050389W WO2020202148A1 WO 2020202148 A1 WO2020202148 A1 WO 2020202148A1 IL 2020050389 W IL2020050389 W IL 2020050389W WO 2020202148 A1 WO2020202148 A1 WO 2020202148A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microbial consortium
- microorganism
- microorganisms
- modulating
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present discourse relates to consortium of microorganisms and uses thereof, for example, for treating cancer
- the human microbiome is a diverse multispecies population of more than trillion microorganisms including bacteria, fungi, archaea, and viruses that collectively play an important role in various physiological process within a host affecting human health and disease. For example, it was shown that the microbiome has tire ability to increase energy extraction from food, to serve as a physical barrier to protect the host from external pathogens and to assist in the development of the host immune system [1]
- compositions of bacterial strains, and their use for treating disease were described GENERAL DESCRIPTION
- the invention relates to a microbial consortium comprising two or more microorganisms, at least one of the two or more microorganisms is present at low-abundance in a microbiome of a reference human subject and at least one other of the two or more microorganisms having at least one of (i) capable of modulating at least one short chain fatty acid (SCFA), (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component.
- SCFA short chain fatty acid
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a microbial consortium comprising two or more microorganisms, at least one of the two or more microorganisms is present at low-abundance in a microbiome of a reference human subject and at least one other of the two or more microorganisms having at least one of (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component.
- the invention relates to a method of treating, preventing, ameliorating, reducing or delaying the onset or the progression of cancer in a human subject in need thereof comprising the step of administering to the subject an effective amount of a microbial consortium comprising two or more isolated microorganism or purified microorganism, at least one of the two or more microorganisms is present at low-abundance in a microbiome of a reference human subject and at least one other of the two or more microorganisms having at least one of (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component.
- the invention relates to a method of treating, preventing, ameliorating, reducing or delaying the onset or the progression of cancer in a human subject in need thereof comprising the step of administering to the subject an effective amount of a microbial consortium and a therapeutically effective amount of an anticancer treatment, the microbial consortium comprising two or more isolated microorganism or purified microorganism, at least one of the two or more microorganisms is present at low-abundance in a microbiome of a reference human subject and at least one other of the two or more microorganisms having at least one of (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component.
- the invention relates to a use of a microbial consortium comprising two or more microorganisms, at least one of the two or more microorganisms is present at low-abundance in a mierobiome of a reference human subject and at least one other of the two or more microorganisms having at least one of (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component in the preparation of a composition for treating cancer in a sub j ect in need thereof.
- the invention relates to a kit comprising a microbial consortium comprising two or more microorganisms, at least one of tire two or more microorganisms is present at low-abundance in a mierobiome of a reference human subject and at least one other of the two or more microorganisms having at least one of (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component or a composition comprising the microbial consortium.
- Figs, 1A -IE are bar graphs showing the Toll-like receptor 4 (TLR4) activation by bacterial strains in RAW cells at various bacteriaxells ratios; lipopolysaccharide (LPS) as positive control (PC) (Fig. 1A), Bacteroides caccae CL03T12C61 (Fig. IB), Cetobacterium somerae ATCC BAA-474 (Fig. 1C), Oenococcus oeni PSU-1 (Fig. ID), Veillonella parvula ATCC 17745 (Fig. IE), results are represented as means ⁇ SEM.
- TLR4 Toll-like receptor 4
- Figs. 2A-2C are bar graphs showing tire Toll-like receptor 2 (TLR2) activation by bacterial strains in RAW cells at various bacteriaxells ratios; LPS as positive control (Fig. 2A), Oenococcus oeni PSU-1 (Fig. 2B), Corynebacterium glyciniphiburn AJ 3170 (Fig. 2C), results are represented as means ⁇ SEM Figs, 3A-3C are boxpiots showing the efficacy of different bacterial strains in stimulating cytokines’ secretion from RAW cells, TNFa (Fig. 3A), 1L6 (Fig. 3B), I L ! b (Fig. 3C), results are provided as median with the interquartile range, and error bars are the 1.5 times interquartile range (whiskers).
- TLR2 Toll-like receptor 2
- Figs. 4A-4C are boxpiots showing the efficacy of different combinations of bacterial strains (Cons. 1, Cons. 2, Cons. 3, Cons. 4, Cons. 5) in stimulating cytokines’ secretion from RAW cells, TNFa (Fig. 4A), IL6 (Fig. 4B), 1 L i b (Fig, 4C), the total concentration of ail bacteria in each consortium was 1CI0 L 8 CFU/ml, results are provided as median with the interquartile range, and error bars are the 1.5 times interquartile range (whiskers).
- Figs. 5A and 5B are bar graphs showing the efficacy of bacterial strains in stimulating cytokines’ secretion from human peripheral blood mononuclear cell (PBMCs), IL6 (Fig. SA), TNFa (Fig. SB), the concentration of each bacterial strain is 1C10 L 8 CFU/ml; results are represented as means ⁇ SEM.
- Figs. 6A to 61 show in vivo effect of bacterial combinations (Cons 1, Cons. 2, Cons. 3) on the response to immune checkpoint therapy for the treatment of breast cancer in a mouse model
- Fig. 6A shows inhibition of tumor growth in bacterial combination- treated mice in addition to anti-PE) 1 therapy compared to anti -PD! only as measured by log 10 of tumor volumes along time, circle - no treatmen t, triangle - Cons. 1 +anti PD-1, rectangular - Cons. 2+anti PD-1, plus sign - Cons. 3+anti PD-1, X - anti -PD1, (**p ⁇ 0.01, ***p ⁇ 0.001); Fig.
- FIG. 6B is a graph showing the time to reach study end-point (calculated from day 29 of the study) (tumor volume of 1000 mnri) for the various treatments;
- Fig. 6C to 6E are boxpiots showing the levels of various cytokines in the plasma of mice following treatment,
- Fig. 6F to 61 are graphs showing immunohistochemistry analysis of expression of specific cell surface markers and inflammation scores from H&E staining of 4 pm sections from paraffin-embedded dissected tumors from mice following treatment. DETAILED DESCRIPTION OF EMBODIMENTS
- the gut microbiome includes a large number of diverse microorganisms that are capable of affecting a variety of physiological process within a host, including for example development and differentiation, activation or suppression of the host's immune system.
- the present disclosure is based on a possible connection between the immune system and cancer therapy and is aimed at using specific microorganisms detected in, isolated from or purified from a microbiome, for example the gut microbiome, that contribute to modulation of the immune system and hence may be used in inhibiting cancer growth and in treatmen t of cancer.
- the inventors have used an array of computational tools utilized to process high-throughput sequencing data and obtained high resolution detection and annotation of microbial genes and pathways as well as microbial taxa. This resulted in a mechanistic understanding of a relationship between an organisms’ (such as a microorganism) and various human cellular processes related to cancer and immune function.
- an organisms such as a microorganism
- several methods such as stringent statistical comparative analyses were applied to enable the identification and selection of specific microorganisms and microbial functions that differentiate between cancer patients that were found to respond to immune checkpoint blockade treatment and cancer patients that were found to be non-responders to this treatment.
- the inventors have thus suggested that the computationally identified microorganisms may he administered, alone or preferably in specific combinations, to a subject in order to enrich the microbiome diversity, induce a pro-inflammatory effective immune response and to treat cancer.
- the inventors further suggested that the identified microorganisms may be used for diagnostic and prognostic purposes, for example for assessing responsiveness of a subject to treatment and for determining treatment protocols.
- the present disclosure provides a microbial consortium.
- the microbial consortium comprises two or more microorganisms that are collectively capable of affecting different functional capabilities, by modulating a number of processes both in the microorganism per se and in the host. Such process may he for example production of short chain fatty acids (SCFAs), activation of dendritic cells, and innate immune activation.
- SCFAs short chain fatty acids
- microorganisms were found to be present at low amounts in the human microbiome and were further found to play a major role in immune mediated processes in a host. As shown in the examples below, these microorganisms, although present at low amounts in the human microbiome, elicit a profound pro-inflammatory response alone and in combinations both in in vitro and in in vivo experiments.
- the present disclosure provides a microbial consortium comprising two or more microorganisms, at least one of the two or more microorganisms is present at low- abundance in a microbiome of a reference human subject.
- the microbial consortium as used herein refers to a mixture/cocktail of microorganisms, including at least one of a bacterium and/or an archaea.
- a microorganism it should be understood as referring to one microorganism species and/or strain as classified under common scientific classification.
- the microorganisms being the subject of tire present disclosure are present in the human microbiome and thus can be isolated and/or purified from any microbiome, such as the human microbiome, by any known method in the art as also detailed below or purified from a biological material (e.g, fecal materials, such as feces or materials isolated from the various segments of the small and large intestines).
- a biological material e.g, fecal materials, such as feces or materials isolated from the various segments of the small and large intestines.
- the term microorganism used herein refers in accordance with some embodiments, to at least one of an isolated microorganism, a purified
- the microbial consortium comprises isolated microorganisms. In some embodiments, the microbial consortium comprises purified microorganisms. In some embodiments, the microbial consortium comprises recombinant microorganisms. In some embodiments, the microbial consortium comprises isolated microorganisms, purified microorganisms or any combination thereof in some embodiments, the microbial consortium comprises isolated microorganisms, purified microorganisms, recombinant microorganisms or any combination thereof. It should be noted that the recombinant microorganisms of the present invention are microorganisms whose genetic makeup has been altered by deliberate introduction of new genetic elements. The recombinant microorganisms may maintain the functions (cellular processes) of the original microorganism .
- the microorganism of the present invention may be at least one of a live microorganism or provided as spores, heat-killed, non-living form of the microorganism, or an extract or a component of the organism.
- the selected/identified microorganisms are capable of treating cancer via modulation of multiple pathways, such as altering the host microbiota or modulating the production of various biological molecules (e.g, SCFA).
- multiple pathways such as altering the host microbiota or modulating the production of various biological molecules (e.g, SCFA).
- the attribution of the microorganisms to each one of the consortiums of the invention was done by considering the multiple functions of each one of the microorganisms and the combined functions, m order to avoid adverse effect such as, for example, damage to the intestinal epithelium.
- the inventors have suggested that the selected microorganisms, while capable of inducing a pro-inflammatory effect and inhibiting cancer progression, would maintain the integrity of the gut barrier. This may be achieved, for example by affecting mucin degradation or modulation of SCFAs in the gut.
- the at least two or more microorganisms in the microbial consortium may possess various biological relationship such that, for example, at least one microorganism may benefit from the at least one other microorganism.
- the metabolic products of one microorganism may be used as a substrate by another member of the consortium or by additional grit commensals, hence increasing the likelihood of intestinal colonization by the microbial consortium or promoting a desired activity of one or more microorganism.
- the combination of at least two microorganisms in the microbial consortium may achieve actions resulting m immune modulation through several underlying, overlapping and complementary mechanisms.
- At least one microorganism in the microbial consortium may be capable of modulating at least one process, at times at least two processes and even at times at least three or at least four process as detailed herein below.
- at least one microorganism in the microbial consortium is present at low-abundance in a microbiome of a reference human subject.
- Abundance in the context of the present disclosure refers to a representation of the relati ve amount (quantity) of a specific microorganism in the microbiome. This amount can be obtained, by any method known in the art.
- various molecular-based methods are available to characterize and quantitate the intestinal microbiota such as traditional clone libraries; direct sequencing using next-generation parallel sequencing technology; denaturing gradient gel electrophoresis and temperature gradient gel electrophoresis; terminal restriction fragment length polymorphism analysis; fluorescent in situ hybridization; and quantitative Polymerase Cham Reaction (PCR).
- computational analysis of sequence data including information on isolated intestinal microorganisms can be used, for example by counting the number of mapped reads to a reference genome.
- relative abundance for each microorganism in the microbiome can be determined and is defined as the number of reads mapped to a reference genome divided by the total number of microbial reads within a given microbiome sample and normalized in methods known in the art (e.g. genome size).
- the term low-abundance as used herein refer to a microorganism that is present in the microbiome of a reference subject in tin amount that is below a predetermined standard value/s or cutoff value/s.
- the predetermined standard value/s or cutoff value/s may be determined as an average value for a large, heterogenous cohort of subjects or alternatively be determined for a specific population of reference subjects.
- the reference human subject is a healthy subject.
- a healthy subject is a subject that is not diagnosed with a disease to be treated using the microbial consortium of the invention.
- the reference human subject is a subject diagnosed with at least one disease, optionally a disease that can be treated using the microbial consortium of the invention.
- low abundance microorganism has an average relative abundance of less than 0.5%, at times less than 0.4%, at times less than 0.3%, at times less than 0.2%, at times even less than 0.1%. In some embodiments, low abundance microorganism has an average relative abundance of between about 0.00001 % to about 0.5%, at times between about 0.0001 % to about 0.4%, at times between about 0.001% to about 0.3%, at times between about 0.01 % to about 0.2%, at times between about 0 01% to about 0.1 % at times between about 0 05% to about 0.1%
- the at least one microorganism present at low abundance in a reference human subject having at least one of the following (i) capable of modulating at least one SCFA and (ii) comprises at least one cell envelope component.
- the cell envelope component in accordance with the present invention is a one that is being recognized by a subject’s immune system or an epithelial cell, such as intestinal epithelial cell.
- the at least one microorganism present at low abundance in a reference human subject is capable of modulating lactate.
- the present disclosure provides a microbial consortium comprising two or more microorganisms, at least one of the two or more microorganisms is present at low-abundance in a microbiome of a reference human subject and having at least one of (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component being recognized by a subject’s immune system or an epithelial cell, such as intestinal epithelial cell.
- the microbial consortium comprises at least one other microorganism.
- the at least one other microorganism having at least one of (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component being recognized by a subject’s immune system or an epithelial cell, such as intestinal epithelial cell.
- the present disclosure provides a microbial consortium comprising two or more microorganisms, at least one of the two or more microorganisms is present at low-abundance in a microbiome of a reference human subject and at least one other of the two or more microorganisms having at least one of (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component being recognized by a subject’s immune system or an epithelial cell, such as intestinal epithelial cell .
- the at least one other microorganism having at least one of (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component recognized by a subject's immune system being recognized by a subject's immune system or an epithelial cell, such as intestinal epithelial cell is at least one microorganism being present at low-abundance a microbiome of a reference human subject.
- the at least one other microorganism having at least one of (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component recognized by a subject's immune system being recognized by a subject's immune system or an epithelial cell, such as intestinal epithelial cell is at least one microorganism characterized by not being present at low-abundance in a microbiome of a reference human subject.
- One or more of the microorganisms of the present invention may be modulator of physiological processes, i.e. capable of modulating at least one physiological process in the microorganism and/or the host.
- a microorganism capable of modulating relates to a microorganism that acts directly (e.g., by binding) or indirectly on a biological entity, such as a receptor or an enzyme, and leads to a modulation of its activation.
- modulation may either activate and increase activation of a physiological/cellular process, or alternatively, decrease and inhibit activation of a physiological/cellular process, specifically, any of these processes, as specified herein.
- modulator therefore includes inhibitors and activators and hence the microorganisms of the present invention may be considered as either inhibitors or activators of a specific process.
- activators are agents that induce, activate, stimulate, increase, facilitate, enhance activation, sensitize or up regulate a physiological/cellular process, e.g., a microorganism that increase/activate a process or any indirect activator.
- Inhibitors are agents that inhibit, partially or totally block stimulation or activation, decrease, prevent, delay activation, inactivate, desensitize, or down regulate a physiological/cellular process, e.g., a microorganism that reduce/decrease a process or any indirect inhibitor.
- modulation in connection with the present invention may encompasses also maintaining for example expression or function.
- modulate as used herein may be used as enhancing secretion of one or more substance, as described herein or maintaining the
- modulation as used in the present invention encompass processes (pathways) within the microorganism(s) and/or within the host.
- microbial-related processes processes that are modulated endogenous in the microorganisms, i.e. microbial- related processes, are all collectively denoted herein as "fi' mctional microbial processes.
- the functional microbial processes may take place in at least one specific type (species or microorganism) microorganism (endogenous process).
- Such microbial processes produce, for example, a microorganism product that may be secreted from the microorganism to affect the host.
- the microbial consortium may, for example, modulate (by activation) a microbial process resulting in the production of SCFA or lactate and their subsequent secretion to the host.
- microorganisms identified by the inventors were found to modulate a variety of cellular processes in a host, denoted herein as [functional host processes”. These processes may be mediated by a microbial component (i.e produced and secreted by a microorganism) directly or indirectly via a host component. Tims, at least one of the two or more microorganisms, for example the at least one microorganism being present at low-abundance in a microbiome of a reference human subject, is capable of modulating a cellular process in a host subject (functional host process).
- the inventors suggested that an interaction exists between a specific process in the microorganisms and a cellular process being activated by this specific feature in a host subject.
- SCFA such as acetic acid, propionic acid or butyric acid
- SCFA may be secreted from the specific microorganism to the host gut and may in turn inhibit the host’s HDACs (histone deaeety!ase) enzymes or activation of a surface component of an immune cell of a host subject.
- microbial cell envelop component such as LPS
- TLRs Toll-like receptors
- the host component may be, for example an enzyme.
- the microbial component may be produced by the microorganism and may be secreted into the host gut.
- modulation of a cellular processes may result in production of a substance.
- producing as used herein refers to production per se of a substance either directly or indirectly in the microorganism, for example by at least one microorganism (for example in the microorganism) or a component thereof (such as an enzyme) or in the host by a component of a host, and also, at times, when the substance is produced within the microorganism, this may also encompasses the secretion of the specific substance from the at least one microorganism into the host's gut and stool.
- the identified microorganisms were capable of modulating a variety of processes, for example activating TLRs, secretion of a variety of pro-inflammatory cytokines and expression of various surface component of an immune cell.
- the microorganisms that are present in low abundance in the in a microbiome of a reference human subject exhibited a profound and substantive modulation (activation, secretion, expression) of a variety of processes both in macrophages and in peripheral blood mononuclear cell (PBMC).
- PBMC peripheral blood mononuclear cell
- the microbial consortium is capable of modulating a variety of process, including the functional microbial processes and/or the junctional host processes, all referred herein collectively as cellular processes.
- the cellular process relates (encompasses) to modulation of at least one of the following (i) a Toll-like receptor (TLR), (ii) a surface component of an immune cell, (iii) nuclear factor kappa-light-chain- enhancer of activated B cells (NF-KB), (iv) a dendritic cell, (v) a pro-inflammatory cytokine and ( vi) gut barrier integrity.
- TLR Toll-like receptor
- NF-KB nuclear factor kappa-light-chain- enhancer of activated B cells
- NF-KB nuclear factor kappa-light-chain- enhancer of activated B cells
- NF-KB nuclear factor kappa-light-chain- enhancer of activated B cells
- NF-KB nuclear factor kappa-light-chain- enhance
- the microbial consortium is capable of modulating of at least one of the following (i) a TLR, (ii) a surface component of an immune cell, (iii) NF-KB, (iv) a dendritic cell, (v) a pro-inflammatory cytokine and (vi) gut barrier integrity.
- the microbial consortium is capable of modulating at least one of the following (i) activating a TLR, (ii) activating a surface component of an immune cell, (iii) activating NF-KB, (iv) activating a dendritic cell, (v) secreting a pro- flammatory ' cytokine and (vi) maintaining or enhancing gut barrier integrity.
- the microbial consortium is capable of modulating of at least one of the following (i) activating a TLR, (ii) activating a surface component of an immune cell and (iii) maintaining a pro-inflammatory cytokine
- the at least one microorganism present at low abundance in a reference human subject is capable of modulating at least one of (i) a TLR, (ii) a surface component of an immune cell, (iii) NF-KB, (iv) a dendritic cell, (v) a pro-inflammatory ' cytokine and (vi) gut barrier integrity.
- the at least one of the two or more microorganisms is capable of modulating at least one of (i) a TLR, (ii) a surface component of an immune cell and (iii) a pro-inflammatory ' cytokine.
- the microbial consortium having at least one of (i) capable of modulating (activating) at least one SCFA, (ii) comprises at least one cell envelope component being recognized by a subject’s immune system or an epithelial cell, such as intestinal epithelial cell, (iii) capable of modulating (activating)at least one TLR, (iv) capable of modulating (activating)a surface component of an immune cell, (v) capable of modulating (acti vating) NF-kB, (vi) capable of modulating (activating)a dendritic cell, (vii) capable of secreting a pro-inflammatory cytokine and (viii) capable of maintaining or enhancing a gut barrier integrity.
- the at least one of the two or more microorganisms for example the at least one of the two or more microorganisms being present at low- abundance in a microbiome of a reference human subject, having at least one of (i) capable of modulating at least one SCFA, (ii) comprises at least one cell envelope component being recognized by a subject’s immune system or an epithelial cell, such as intestinal epithelial cell, (in) capable of modulating at least one TLR, (iv) capable of modulating a surface component of an immune cell, and (v) capable of modulating a pro- mflammatory cytokine.
- the microbial consortium comprises at least one microorganism, for example die at least one of the two or more microorganisms being present at low-abundance in a microbiome of a reference human subject, that is capable of modulating/activating at least one SCFA
- SCFA that are being produced by the gut microbiome sen/e as an energy source to a host intestinal epithelium and regulate gut motility, inflammation, immune function, glucose homeostasis, and energy harvesting.
- the SCFA comprises at least one of an acetic acid, a propionic acid, a butyric acid, a valeric acid, an isovaleric acid, a formic acid, an isobutyric acid and any combination thereof.
- the SCFA comprises at least one of an acetic acid, a propionic acid, a butyric acid and any combination thereof.
- the microbial consortium comprises at least one microorganism, for example the at least one microorganism being present at low- abundance in a microbiome of a reference human subject, that is capable of secreting at least one of an acetic acid, a propionic acid, a butyric acid, a valeric acid, an isovaleric acid, a formic acid, an isobutyric acid, lactate and any combination thereof.
- the microbial consortium comprises at least one microorganism, for example the at least one microorganism being present at low- abundance in a microbiome of a reference human subject, that is capable of secreting at least one of an acetic acid, a propionic acid, a butyric acid, lactate and any combination thereof.
- the microbial consortium comprises at least one microorganism, for example the at least one microorganism being present at low- abundance in a microbiome of a reference human subject, that comprises at least one cell envelope component.
- cell envelope component refers to a structural/ chemical entity that reside on or embedded in the microorganism's membrane or cell wall or outer membrane.
- the ceil envelope components in accordance with some embodiments, have an ability to be recognized by a subject (host) immune system and in accordance with some other embodiments to activate the host immune system or to be recognized by a subject’s epithelial cell, such as intestinal epithelial cell.
- PAMPs pathogen-associated molecular patterns
- PRRs pattern recognition receptors
- the cell envelope component is or comprises at least one of a lipoprotein, a lipoglycan, a peptidoglycan, a lipopolysaceharide, a polysaccharide, a flagellin, a protein, a peptide, and a sugar residue.
- the cell envelope component is or comprises a peptidoglycan.
- the peptidoglycan is a pseudopeptidoglycan.
- Pseudopeptidoglycan (also known as pseudomurein) is a major cell wail component of several archaea.
- the pseudopeptidoglycan is N-acetylglucosamine, N-acetyltaiosaminuronic acid or any combination thereof.
- the cell envelope component is or comprise a polysaccharide.
- the polysaccharide is an O-Antigen or a glucan.
- O-Antigens also known as O-specific polysaccharides or O-side chains
- LPS surface lipopoly saccharide
- a glucan is a polysaccharide derived from D-glucose, linked by glycosidic bonds.
- Glucams include alpha- glucans and beta-glucans and numbers clarify the type of O-glycosidic bond.
- the ceil envelope component is a biopolymer comprising a galactose and arabinose residues. In some other embodiments, the biopolymer is an arabinogalactan.
- the cell envelope component is or comprises a lipid residue.
- the lipid residue is or comprises an archaea! lipid or a lipid A
- Archaea lipids are characterized by comprising ether-linked lipids based on 2,3- dialkyl-srt-glycerol backbones.
- Non-limiting examples of archaea lipids include archaeol and caldarchaeol
- the cell envelope component is or comprises at least one of a lipoprotein, a lipoglycan and a lipopoly saccharide. In some other embodiments, the cell envelope component is a !ipopoh saccharide comprising lipid A.
- the ceil envelope component is or comprises at least one of a pseudopeptidoglycans, archaeal lipids, an O-antigens, lipid A, arabmogalactans and beta glucan
- a cell envelope component as detailed herein can be determined by any method known in the art, for example by using computational tools to identify genes that are encoding for the synthesis of specific cell envelope components detailed herein.
- such cell envelope component can be determined by any known method in the art.
- the microbial consortium is capable of activating at least one
- TLR The TLR family plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular paterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity . The various TLRs exhibit different patterns of expression.
- PAMPs pathogen-associated molecular paterns
- the TLR is selected from the group consisting of TLRi, TLR2, TLRS, TLR4, TLRS, TRL6, TLR7, TLR8, TLR9, and any combination thereof.
- the microbial consortium comprises at least one microorganism, for example the at least one microorganism being present at low- abundance in a microbiome of a reference human subject, is capable of modulating at least one of TLRI , TLR2, TLRS, TLR4, TLR5, TRL6, TLR7, TLRS, TLR9 and any combination thereof.
- the microbial consortium comprises at least one microorganism, for example the at least one microorganism being present at low- abundance in a microbiome of a reference human subject, is capable of modulating at least one of TLR2, TLR4, TLR5, TRL6 and any combination thereof.
- the microbial consortium comprises at least one microorganism, for example the at least one microorganism being present at low- abundance in a microbiome of a reference human subject, is capable of modulating at least one of TLR2, TLR4 and any combination thereof
- the microbial consortium is capable of activating at least one immune cell such as a T cell, a B cell, a NK cells Antigen presenting cell (APCs) such as macrophages or dendritic cells or a surface component of an immune cell.
- APCs Antigen presenting cell
- the surface component of an immune cell comprises at least one cluster of differentiation (CD).
- cluster of differentiation also known as cluster of designation or classification determinant
- CD molecules often act as receptors or ligands important to the cell.
- the at least one cluster of differentiation is at least one of CD4, CDS, CD40, CD68, CD80, CD86, CD 197, CD45, GDI lb, CD 103 and any combination thereof.
- the microbial consortium comprises at least one microorganism, for example the at least one microorganism being present at low- abundance in a microbiome of a reference human subject, is capable of modulating the expression of at least one of CD4, CD8, CD40, CD68, CD80, CD86, CD197, CD45, CD1 lb, CD 103 and any combination thereof.
- the microbial consortium comprises at least one microorganism, for example the at least one microorganism being present at low- abundance in a microbiome of a reference human subject, is capable of modulating the expression of at least one of CD 8 and CD68 and any combination thereof.
- the microbial consortium is capable of activating NF-KB.
- NF-KB is a protein complex that controls transcription of DNA, cytokine production and ceil survival and plays a key role in regulating the immune response to infection.
- the microbial consortium is capable of activating a dendritic cell.
- Dendritic cells are antigen-presenting cells of the immune system and their main function is to process antigen material and present it on the cell surface to the T ceils of the immune system. Activated DCs migrate to the lymph nodes to interact with T ceils and B cells to initiate and shape the adaptive immune response.
- the microbial consortium is capable of activating an mflammasome.
- An inflammasome is a multiprotein oligomer responsible for the activation of inflammatory responses and promotes the maturation and secretion of pro- inflammatory cytokines, such as Interleukin 1 b (IL-Ib) and Interleukin 18 (IL-18)
- the microbial consortium is capable of modulating an pro- inflammatory cytokine.
- a pro-inflammatory cytokine (also denoted as an inflammatory' ⁇ cytokine) is a type of signaling molecule (a cytokine) that is secreted from immune cells like helper T cells (Th) and macrophages, and certain other cell types that promote inflammation.
- a cytokine a type of signaling molecule that is secreted from immune cells like helper T cells (Th) and macrophages, and certain other cell types that promote inflammation.
- Non-limiting examples of pro-inflammatory cytokines include interleukin- 1 (IL- 1), IL-12, IL-18, tumor necrosis factor alpha (TNF-a), interferon gamma (IFNy), and granulocyte-macrophage colony stimulating factor (GM-CSF).
- IL-1 interleukin- 1
- IL-12 IL-12
- IL-18 tumor necrosis factor alpha
- IFNy interferon gamma
- GM-CSF granulocyte-macrophage colony stimulating factor
- the pro-inflammatory cytokine comprises at least one of interleukin-1 (IL-1), IL-2, IL-Ib, IL-6, IL-12, IL-18, 1L-22, 1L-23 tumor necrosis factor alpha (TNF-a), interferon gamma (IFNy), and granulocyte-macrophage colony stimulating factor (GM-CSF).
- IL-1 interleukin-1
- IL-2 interleukin-2
- IL-Ib IL-6
- IL-12 IL-18
- IFNy interferon gamma
- GM-CSF granulocyte-macrophage colony stimulating factor
- the pro-inflammatory' ⁇ cytokine comprises at least one of at least one of TL-I b, IL-6, IL-12, TNF-a, IFNy and any combination thereof.
- the microbial consortium comprises at least one microorganism, for example the at least one microorganism being present at low- abundance in a microbiome of a reference human subject, is capable of secreting at least one of TL- 1 , IL-Ib, IL-6, IL-12, IL-18, TNF-a, IFNy, GM-CSF and any combination thereof.
- the microbial consortium comprises at least one microorganism, for example the at least one microorganism being present at low- abundance in a microhiome of a reference human subject, is capable of secreting at least one of IL-Ib, IL-6, IL-12, TNF-a and any combination thereof.
- the microbial consortium is capable of activating secretion of tumor necrosis factor alpha (TNFrx).
- TNFa is a cell signaling protein (cytokine) involved in systemic inflammation and is one of the cytokines that make up the acute phase reaction. The primary' role of TNF is in the regulation of immune cells.
- the microbial consortium is capable of activating secretion of interferon gamma (IFNy).
- IFNy interferon gamma
- IF y is a dimerized soluble cytokine that is critical for innate and adaptive immunity against viral, some bacterial and protozoal infections. It is an important activator of macrophages and inducer of Class II major histocompatibility complex (MHC) molecule expression.
- MHC major histocompatibility complex
- the microbial consortium is capable of activating mucin degradation.
- Activating mucin degradation in the context of tire present disclosure refers to functioning to degrade host mucins.
- Host mucins are consisting predominantly of core 1-4 mucin-type O-glycans containing a- and b- linked N-acetyl-gaJactosamine, galactose and N-acetyl-glucosamine. These core structures are further elongated and frequently modified by fucose and sialic acid sugar residues via al, 2/3/4 and a2,3/6 linkages, respectively.
- microorganisms that is present in low abundance were shown in the examples to modulate a variety of process.
- the at least one microorganism present at low abundance in a reference human subject is capable of modulating at least one of acetic acid, propionic acid and butyric acid.
- the at least one microorganism present at low abundance in a reference human subject comprises at least one of pseudopeptidoglycans, archaeal lipids, an O-antigens, lipid A, arabinogaiactans and beta glucan.
- the at least one microorganism present at low abundance in a reference human subject is capable of at least one of (i) modulating at least one of acetic acid, propionic acid and butyric acid and (ii) comprises at least one of pseudopeptidoglycans, archaeal lipids, an O-antigens, lipid A, arabinogalactans and beta glucan.
- the at least one microorganism present at low abundance in a reference human subject is capable of modulating at least one of TLR2, TLR4, TLR5.TLR6. TLR7 and TLR8.
- the at least one microorganism present at low abundance in a reference human subject is capable of at least one of (i) modulating at least one of acetic acid, propionic acid butyric acid, TLR2, TLR4, TLR5,TLR6, TLR7 and TLR8 and (ii) comprises at least one of pseudopeptidoglycans, archaeal lipids, an O- antigens, lipid A, arabinogalactans and beta glucan.
- the at least one microorganism present at low abundance in a reference human subject is capable of modulating at least one of TLR2 and TLR4.
- the at least one microorganism present at low abundance in a reference human subject is capable of modulating at least one of CDS and CD68.
- the at least one microorganism present at low abundance in a reference human subject is capable of modulating at least one of TLR2, TLR4, CDS and CD68.
- the at least one microorganism present at low abundance in a reference human subject is capable of modulating a dendritic cell.
- the at least one microorganism present at lo abundance in a reference human subject is capable of modulating at least one of IL-Ib, IL-6, IL-12, TNF-a, and IFNy. In some embodiments, the at least one microorganism present at low abundance in a reference human subject is capable of modulating at least one of IL-I b, IL-6, IL-12, and TNF-a.
- tire at least one microorganism present at low' abundance in a reference human subject is capable of at least one of modulating TLR2, modulating TLR4, modulating TLR5, modulating TLR6, modulating TLR7, modulating TLR8, secreting of IL-Ib, secreting of IL-6, secreting of IL-12, secreting of TNF-a, secreting IFNy, expressing CD8 and expressing CD68.
- the at least one microorganism present at low abundance in a reference human subject is capable of at least one of modulating TLR2, modulating TLR4, secreting of IL-I b, secreting of IL-6, secreting of IL-12, secreting of TNF-a, secreting IFNy, expressing CD8 or expressing CD68
- the at least one microorganism present at low* abundance in a reference human subject is capable of at least one of (i) modulating at least one of an acetic acid, propionic acid, butyric acid, TLR2, TLR4, TLR5, TLR6, TLR7, TLR8, CD8, CD68, IL-Ib, IL-6, IL-12, TNF-a, and IFNy, and (ii) comprises at least one of pseudopeptidoglycans, archaeal lipids, an O-antigens, lipid A, arabinogalactans and beta glucan
- the at least one microorganism present at low* abundance in a reference human subject is capable of at least one of (i) modulating at least one of an TLR2, TLR4, CD8, CD68, IL-Ib, IL-6, IL-12, and TNF-a and (ii) comprising at least one of pseudopeptidoglycans, archaeal lipids, an O-antigens, lipid A, arabinogalactans and beta glucan.
- the activation of the immune response is achieved by the unique identified microorganisms.
- tire microbial consortium comprises at least one microorganism from the Methanosphaera genus, Oenococcus genus, Cetohacterium genus, Co ryne bacterium genus and Clostridium genus.
- the microbial consortium comprises at least one, at least two, at least three microorganism from the Oenococcus genus, Cetohacterium genus, Coryne bacterium genus and Clostridium genus.
- the at least one microorganism of low abundance is at least one of the Methanosphaera genus, Oenococcus genus, Cetohacterium genus, Corynehacterium genus and Clostridium genus. In some embodiments, the at least one microorganism of low abundance is at least one of the Oenococcus genus, Cetohacterium genus, Corynebacteriurn genus and Clostridium genus.
- die microbial consortium comprises at least one microorganism from th Q Methanosphaera genus.
- Melhanosphaera genus may be denoted by Taxonomy ID (or taxid): 2316.
- Methanosphaera is a genus of microorganisms (archaea) within the family Methanobacteriaceae.
- the microbial consortium comprises at least one microorganism from the Oenococcus genus
- Oenococcus genus may be denoted by Taxonomy ID: 46254.
- Oenococcus is a genus of gram -positive bacteria, within the family Leuconostocaceae.
- Non-limiting examples of Oenococcus genus include Oenococcus oeni and Oenococcus kitaharae.
- the microbial consortium comprises at least one microorganism from the Cetohacterium genus.
- Cetobacterium genus may be denoted by Taxonomy ID: 180162 Cetobacterium. is a genus of Grain-negative bacteria from the family of Fusobacteriaceae .
- the microbial consortium comprises at least one m icroorganism species (type) from the Corynebacteriurn genus.
- Coryne bacterium genus may be denoted by Taxonomy ID: 1716.
- Corynebacteriurn is a genus of bacteria that are Gram-positive and aerobic and are bacilli (rod-shaped).
- die microbial consortium comprises at least one microorganism from the Clostridium genus.
- Clostridium genus may be denoted by Taxonomy ID: 1485.
- Clostridium is a genus of Gram-positive bacteria.
- the microbial consortium comprises at least one microorganism from the Methanosphaera stadtmanae species, Oenococcus oeni species, Clostridium cellulovorans species, Cetobacterium somerae species, Corynebacteriurn glyciniphilum species and Clostridium tyrobutyricum species.
- the microbial consortium comprises at least one, at least two, at least three microorganism from the Oenococcus oeni species, Clostridium cellulovoram species, Cetobacierium somerae species, Corynebacterium glyciniphilum species and Clostridium tyrobutyricum species.
- the at least one microorganism of low abundance is at least one from th e Methanosphaera stadtmanae species, Oenococcus oerti species, Clostridium cellulovoram species, Cetobacierium somerae species, Corynebacterium glyciniphilum species and Clostridium tyrobutyricum species.
- the at least one microorganism of low abundance is at least one from the Oenococcus oeni species, Clostridium cellulovoram species, Cetobacierium somerae species, Corynebacterium glyciniphilum species and Clostridium tyrobutyricum species.
- the at least one microorganism of low abundance is at least one from the Oenococcus oeni species, Cetobacierium somerae species, Corynebacterium glyciniphilum species and Clostridium tyrobutyricum species.
- the at least one microorganism of low abundance is at least one from the Clostridium cellulovoram species. Cetobacierium somerae species, and Clostridium tyrobutyricum species.
- the at least one microorganism of low abundance is at least one from the Clostridium cellulovoram species and Cetobacierium somerae species.
- the microbial consortium comprises at least one microorganism from the Methanosphaera stadtmanae species.
- Methanosphaera stadtmanae species may be denoted by Taxonomy ID: 2317.
- the microbial consortium comprises at least one microorganism from the Oenococcus oeni species.
- Oenococcus oeni species may be denoted by Taxonomy ID: 1247.
- the microbial consortium comprises at least one microorganism from the Cetobacierium somerae species.
- Cetobacierium somerae species may be denoted by Taxonomy ID: 188913.
- the microbial consortium comprises at least one microorganism from the Corynebacterium glyciniphilum species. Corynebacterium glyciniphilum species may be denoted by Taxonomy ID: 1404244. In some embodiments, the microbial consortium comprises at least one microorganism from the Clostridium tyrobuiyricum species. Clostridium tyrobuiyricum species may be denoted by Taxonomy ID: 1519.
- die microbial consortium comprises at least one microorganism from the Clostridium cellulovorans species.
- Clostridium cellulovorans species may be denoted by Taxonomy ID: 1493.
- identification of microorganism from a biological sample of a human subject may be done using any conventional method in the microbiology field. For example and without being limited thereto identification of bacteria from a biological sample of a human subject may be done using 16S rRNA (ribosomal RNA) sequencing. Identification of isolated microorganism may be done by conducting similarity analysis between the 16S rRNA gene of the isolated microorganism to different microorganism's I6S rRNA gene sequences available in database. This analysis may be done in order to explore tire similarity between a given sequence and all of the available sequences in a database and obtaining the best matched sequences by calculation of a score for the examined similarity. Identity analysis may be conducted by any appropriate program, for example Basic Local Alignment Search Tool (BLAST® ) ) using publicly available databases, for example National Center for Biotechnology Information (NCBI).
- BLAST® Basic Local Alignment Search Tool
- At least one of the two or more microorganisms comprises 16S rRNA sequences having between 85% to 99%, at times between 90% to 99%, at times between 95% to 99%, at times between 96% to 99%, at times between 97% to 99%, at times between 98% to 99% identity with at least one nucleic acid sequences selected from SEQ ID NQ: 1, SEQ ID NO: 2. SEQ ID NQ:3, SEQ ID NO:4 , SEQ ID NO 5 and SEQ ID NO: 6.
- At least one of the two or more microorganisms comprises 16S rRNA sequences having at least at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% identity with at least one nucleic acid sequences selected from SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. It should be noted that each one of the % identity constitutes a separate embodiment of the invention.
- the threshold sequence identity may be 85%, at times 86%, at times 87%, at times 88%, at times 89%, at times 90%, at times 91%, at times 92%, at times 93%, at times 94%, at times 95%, at times 96%, at times 97%, at times 98%, at times 99%, at times 99 5% with each one of the % identity denoted herein constitute a separate embodiment of the invention
- identity refers to two or more nucleic acid sequences, that are the same.
- sequence identity encompasses transcription changes of DNA to RNA, e.g T and U are considered identical.
- the identity may exist over a region of a sequence that is considered by those versed in the art as the variable region of the 16S rRNA. In some embodiments, the identity exists over the length the 16S rRNA or a portion thereof of the variable region.
- % identity between two or more nucleic acid sequences is determined for the two or more sequences when compared and aligned for maximum correspondence.
- sequences (nucleic acid) as described herein having % identity are considered to have tire same function/activity of the original sequence to which identity is calculated to.
- the microbial consortium comprises at least Oenococcus oeni PSU-1.
- Oenococcus oeni PSU-1 may be denoted by Taxonomy ID: 203123
- the 16S rRNA sequence of Oenococcus oeni PSU-1 is provided by SEQ ID NO: 1.
- the microbial consortium comprises at least Clostridium tyrohutyricum KCTC 5387.
- Clostridium tyrohutyricum KCTC 5387 may be denoted by Taxonomy ID: 1121342.
- the 16S rRNA sequence of Clostridium tyrohutyricum KCTC 5387 is provided by GenBank accession No. NR 044718.2 (SEQ ID NO:2).
- the microbial consortium comprises at least Cetobacterium somerae ATCC BAA-474.
- Cetobacterium sornerae ATCC BAA-474 may be denoted by Taxonomy ID: 1319815.
- the 16S rRNA sequence of Cetobacterium somerae ATCC BAA-474 is provided by GenBank accession No. AJ438155.2 (SEQ ID NQ:3).
- the microbial consortium comprises at least Corynehacterium glyciniphilum AJ 3170.
- Corynebacterium glyciniphilum AJ 3170 may he denoted by Taxonomy ID: 1404245.
- the 16S rRNA sequence of Corynebacterium glyciniphilum AJ 3170 is provided by GenBank accession No. NR_I21782.1 (SEQ ID NO:4).
- the microbial consortium comprises at least Clostridium cellulovorans 743B.
- Clostridium cellulovorans 743B may be dented by Taxonomy ID: 573061.
- the 16S rRNA sequence of Clostridium cellulovorans 743B is provided by GenBank accession No. NR_119029.1 (SEQ ID NO:5).
- the microbial consortium comprises at least Methanosphaera stadtmanae DSM3091.
- Methanosphaera stadtmanae DSM3091 may be denoted by Taxonomy ID: 339860.
- the 16S rRNA sequence of Methanosphaera stadtmanae DSM3091 is provided by GenBank accession No. NR_028236. I (SEQ ID NO: 6).
- the microbial consortium comprises two microorganisms, as identified above. In some embodiments, the microbial consortium comprises a combination of two, three, four, five or more microorganisms as identified above.
- At least one of the two or more microorganisms in the microbial consortium comprises 16S rRNA sequence of at least one of SEQ ID NO: !, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO 6.
- the two or more microorganisms in the microbial consortium for example being of low abundance in the microbiome of a reference subject, comprises 16S rRNA sequence of at least two of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID N():4, SEQ ID NO:5 and SEQ ID NO:6.
- the microbial consortium comprises at least one microorganism, at least two, at least three, at least four and at times five of low' abundance having a 16S rRNA sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NG:3, SEQ ID NG:4 and SEQ ID NO:5.
- the microbial consortium comprises in some embodiments at least one, in some embodiments at least two, in some embodiments at least three, in some embodiments at least four microorganisms having a 16S rRNA sequence as denoted by SEQ ID NO: l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5.
- the microbial consortium comprises in some embodiments one, in some embodiments two, in some embodiments three, in some embodiments four, in some embodiments five microorganisms having a 16S rRNA sequence as denoted by SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NQ:3, SEQ ID NO:4 and SEQ ID NO:5.
- the microbial consortium comprises at least one, at least two or more microorganisms selected from Methanosphaera stadtmanae DSM3091, Oenococcus oeni PSU-1, Clostridium tyrobutyricum KCTC 5387, Cetobacterium somerae ATCC BAA -474, Corynebacterium glyciniphilum AJ 3170, and Clostridium celhdovorans 743B
- the microbial consortium comprises two or more microorganisms selected from Methanosphaera stadtmanae DSM3091, Oenococcus oeni PSU-1, Clostridium tyrobutyricum KCTC 5387, Cetobacterium somerae ATCC BAA- 474.
- the microbial consortium comprises one, two, three, four or five microorganisms selected from Oenococcus oeni PSU-1, Clostridium tyrobutyricum KCTC 5387, Cetobacterium somerae ATCC BAA-474, Corynebacterium glyciniphilum AJ 3170, and Clostridium celhdovorans 743B.
- the microbial consortium comprises one, two, three or four microorganisms selected from Oenococcus oeni PSU-1, Clostridium tyrobutyricum KCTC 5387, Cetobacteriu somerae ATCC BAA-474 and Corynebacterium glyciniphilum AJ 3170.
- the microbial consortium comprises one, two or three microorganisms selected from Cetobacterium somerae ATCC BAA-474, Clostridiu tyrobutyricum KCTC 5387, and Clostridium cellulovorans 743B.
- the microbial consortium comprises one or two microorganisms selected from Cetobacterium somerae ATCC BAA-474 and Clostridium tyrobutyricum KCTC 5387.
- the microbial consortium may comprise also at least one high -abundance microorganism from a microbiome of a human reference subject.
- the high-abundance microorganism may be the same microorganism as the microorganism secreting at least one of (i) capable of at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component.
- the high-abundance microorganism may be a different m icroorganism than the microorganism secreting at least one of (i) capable of at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component.
- the high-abundance microorganism may be a different microorganism than the microorganism modulating (producing and/or secreting) a short chain fatty acid (SCFA).
- SCFA short chain fatty acid
- the high-abundance microorganism may be a different microorganism than the microorganism modulating (producing and/or secreting) lactate.
- the high-abundance microorganism may be a different microorganism than the microorganism comprises at least one cell envelope component
- the microbial consortium comprises two or more microorganisms, at least one of the two or more microorganisms is present at low-abundance in a microbiome of a reference human subject and at least one other of the two or more microorganisms is present at high-abundance in a microbiome of a reference human subject and having at least one of (i) capable of at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component.
- the microbial consortium comprises three or more microorganisms, at least one of the three or more microorganisms is present at low- abundance in a microbiome of a reference human subject, at least one other of the three or more microorganisms secretes at least one of having at least one of (i) capable of at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component or a different bacteria and at least one of the three or more microorganisms is present at high-abundance in a microbiome of a reference human subject.
- the term high-abundance as used herein refer to a microorganism that is present in the microbiome of a reference subject in an amount that is above a predetermined standard value/s or cutoff value/s.
- the predetermined standard value/s or cutoff value/s may be determined as an average value for a large, heterogenous cohort of subjects or alternatively be determined for a specific population of reference subjects.
- the reference human subject is a healthy subject.
- a healthy subject is a subject that is not diagnosed with a disease to be treated using the microbial consortium of the invention.
- the reference human subject is a subject diagnosed with at least one disease, optionally a disease that can be treated using the microbial consortium of the invention.
- high abundance microorganism has an average relative abundance of more than 0.5%, at times more than 0.6%, at times more than 0.7%, at times more than 0.8%, at times even more than 0.9%, at times even more than 1.5%, at times even more than 2%. In some embodiments, high abundance microorganism has an average relative abundance of between about 0.5% to about 5%, at times between about 0.6% to about 5%, at times between about 0 7% to about 5%, at times between about 1% to about 5%, at times between about 1.5% to about 5% at times between about 2% to about 5%.
- the high abundance microorganism carries a cell envelope component that is recognized by a subject’s immune system. In some embodiments, the high abundance microorganism carries a cell envelope component that activates a subject’s immune system as described herein.
- the high-abundance microorganism comprises at least one microorganism from the Bacteroides genus, Ruminococcus genus, Lactobacillus genus, Veillonella genus. Bifidobacterium genus, Alistipes genus and Akkermansia genus.
- the high-abundance microorganism comprises at least one m icroorganism from the Bacteroides genus, Lactobacillus genus, or Veillonella genus.
- the high-abundance microorganism comprises at least one microorganism from the Bacteroides genus.
- Bacteroides genus may be dented by T axonomy ID : 816.
- Bacteroides i s a genus of Gram -negative, obligate anaerobic bacteria.
- the high-abundance microorganism comprises at least one m icroorganism from the Ruminococcus genus. Ruminococcus genus may he denoted by Taxonomy ID: 1263. Ruminococcus is a genus of bacteria in the class Clostridia that are anaerobic, Grarn -positive microbes.
- the high-abundance microorganism comprises at least one microorganism species or stain from the Lactobacillus genus.
- Lactobacillus genus may be dented by Taxonomy ID: 1578.
- Lactobacillus is a genus of Gram-positive, facultative anaerobic or microaerophilic, rod-shaped, non-spore-forming bacteria that are a major part of the lactic acid bacteria group (i.e., they convert sugars to lactic acid).
- the high-abundance microorganism comprises at least one microorganism species or strain from the Veillonella genus.
- Veillonella genus may be dented by Taxonomy ID: 29465.
- Veillonella is a genus of Gram-negative bacteria anaerobic cocci, known for its lactate fermenting abilities.
- the high-abundance microorganism comprises at least one microorganism species or strain from the Bifidobacterium genus.
- Bifidobacterium genus may be dented by Taxonomy ID: 1678.
- Bifidobacterium is a genus of gram-positive, nonmotile, often branched anaerobic bacteria.
- the high-abundance microorganism comprises at least one m icroorganism species or strain from the Alistipes genus.
- Alistipes genus may be dented by Taxonomy ID: 239759.
- Alistipes is a genus in the phylum Bacteroidetes.
- the high-abundance microorganism comprises at least one microorganism species or strain from the Akkermansia genus.
- Akkermansia genus may be dented by Taxonomy ID: 239934 .
- Akkermansia is a genus in the phylum Verrucomicrobia.
- the microbial consortium comprises at least one microorganism from the Bacteroides caccae species, Ruminococcus albus species, Lactobacillus casei species, Veillonella parvula species, Alistipes putredinis species, Bifidobacterium breve species and Akkermansia muciniphila species.
- the microbial consortium comprises at least one microorganism, at least two microorganisms, at least three microorganisms from the Bacteroides caccae species, iMCtobacillus casei species or Veillonella parvula species. In some embodiments, the microbial consortium comprises at least one microorganism, at least two microorganisms from the Bacleroides caccae species, or
- die microbial consortium comprises at least one microorganism from die Ruminococcus albus species. Ruminococcus albus species may he denoted by Taxonomy ID: 1264.
- the microbial consortium comprises at least one microorganism from the Lactobacillus casei species.
- Lactobacillus casei species may be denoted by Taxonomy ID: 1582.
- die microbial consortium comprises at least one m icroorganism from the Veillonella parvula species.
- Veillonella parvula species may be denoted by Taxonomy ID: 29466.
- the microbial consortium comprises at least one microorganism from the Alistipes putredmis species.
- Alistipes putredinis species may be denoted by Taxonomy ID: 28117.
- the microbial consortium comprises at least one microorganism from the Bifidobacterium breve species.
- Bifidobacterium breve species may be denoted by Taxonomy ID: 1685.
- the microbial consortium comprises at least one microorganism from the Akkermansia muciniphila species.
- Akkermansia muciniphila species may be denoted by Taxonomy ID: 239935.
- the microbial consortium comprises at least one microorganism from the Bacleroides caccae species.
- Bacteroides caccae species may be denoted by Taxonomy ID: 47678.
- At least one of the two or more microorganisms comprises 16S rRNA sequences having between 85% to 99%, at times between 90% to 99%, at times between 95% to 99%, at times between 96% to 99%, at times between 97% to 99%, at times between 98% to 99% identity with at least one nucleic acid denoted by SEQ ID NO: 7.
- SEQ ID NO: 8. SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 1 1, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14, at times with at least one nucleic acid denoted by SEQ ID NO: 7.
- At least one of the two or more microorganisms comprises 16S rRNA sequences having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity with at least one nucleic acid denoted by SEQ ID NO: 7.
- SEQ ID NO: 10 SEQ ID NO: 1 1, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14, at times with at least one nucleic acid denoted by SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9. It should be noted that each one of the % i dentity constitutes a separate embodiment of the invention.
- the threshold sequence identity may be 85%, at times 86%, at times 87%, at times 88%, at times 89%, at times 90%, at times 91%, at times 92%, at times 93%, at times 94%, at times 95%, at times 96%, at times 97%, at times 98%, at times 99% with each one of the % identity denoted herein constitute a separate embodiment of the invention
- the high-abundance microorganism comprises at least one of Bacteroides caccae CL03T12C61, Ruminococciis albus 7, Lactobacillus case! ATCC27139, Veillonella parvula ATCC 17745, Bifidobacterium breve ATCC 15700, AH stipes putredinis DSM 17216, Akkermenia mucimphila ATCC BAA-835 and Akkermansia muciniphila YL44
- the high-abundance microorganism comprises at least one, at least two of Bacteroides caccae CL03T12C61, Lactobacillus casei ATCC27J 39 or Veillonella parvula ATCC 17745.
- the high-abundance microorganism comprises one, two or three of Bacteroides caccae CL03T12C6I , Lactobacillus casei ATCC27139 or Veillonella parvula ATCC 17745.
- the high -abundance microorganism comprises one, two or three of Bacteroides caccae CL03T12C61 or Veillonella parvula A TCC 17745.
- the high-abundance microorganism comprises one, two or three of Lactobacillus casei A TCC27139 or Veillonella parvula A TCC 17745. In some embodiments, the high-abundance microorganism comprises one, two or three of Lactobacillus cases A TCC27139 or Bacieroides caccae CL03T12C61.
- the high-ahundance microorganism comprises Veillonella parvula ATCC 17745.
- Veillonella parvula ATCC 17745 may be denoted by Taxonomy ID: 686660.
- the 16S rRNA sequence of Veillonella parvula ATCC 17745 is provided by Gene Bank accession No. AY995769.1 (SEQ ID NO ;).
- the high-abundance microorganism comprises Bacieroides caccae CL03T12C6I.
- Bacieroides caccae CL03T12C61 may be denoted by Taxonomy ID: 997873 Tire 16S rRNA sequence of Bacieroides caccae CL03T12C61 is provided by SEQ ID NO: 8
- the high-abundance microorganism comprises
- Lactobacillus cases ATCC27139 The 16S rRNA sequence of iMctobacislus cases A TCC27139 is provided by Gene Bank accession No. AB531131.1 (SEQ ID NO: 9)
- the high-abundance microorganism comprises
- Ruminococcus albus 7 may be denoted by Taxonomy ID: 697329.
- the 16S rRN A sequence of Ruminococcus albus 7 is provided by Gene Bank accession No. NR_025929.1 (SEQ ID NO: 10).
- the high-abundance microorganism comprises
- Bifidobacterium breve ATCC 15700 Bifidobacterium breve ATCC 15700.
- Bifidobacterium breve ATCC 15700 may be denoted by Taxonomy ID: 518634.
- the 16S rRNA sequence of Veillonella parvula ATCC 17745 is provided by Gene Bank accession No. NR 040783.1 (SEQ ID NO: 1 1).
- the high-abundance microorganism comprises Alistipes putredinis DSM 17216
- Alistipes putredinis DSM 17216 may be denoted by Taxonomy ID: 445970.
- the 16S rRNA sequence of Alistipes putredinis DSM 17216 is provided Gene Bank accession No. NR 025909.1 (SEQ ID NO: 12)
- the high-abundance microorganism comprises Akkermansia mucmiphila ATCC BAA-835.
- Akkermansia muciniphila ATCC BAA-835 may be denoted by Taxonomy ID: 349741.
- the 16S rRNA sequence of Akkermansia mucmiphila ATCC BAA-835 is provided by Gene Bank accession No. NR_042817. l (SEQ ID NO: 13).
- the high-abundance microorganism comprises Akkermansia muciniphila YL44.
- the 16S rRNA sequence of Akkermansia muciniphi!a YL44 is provided by SEQ ID NO: 14.
- a microbial consortium comprising two or more purified or isolated microorganisms, at least one of the two or more microorganisms is present at low abundance in a reference human subject being capable of at least one of (i) modulating at least one of an acetic acid, propionic acid, butyric acid, TLR2, TLR4, TLR5, TLR6, TLR7, TLR8, CDS, CD68, IL-Ib, IL-6, IL-12, and TNF-a and IFNy and (ii) comprises at least one of pseudopeptidoglycans, archaeal lipids, an O-antigens, lipid A, arabinogalactans and beta glucan and at least one different microorganism of the two or more microorganisms carries a cell envelope component that is recognized by a subject’s immune system.
- the at least one different microorganism may be a microorganism
- a microbial consortium comprising two or more purified or isolated microorganisms, at least one of the two or more microorganisms is present at low abundance in a reference human subject being capable of at least one of (i) modulating at least one of TLR2, TLR4, TLR5, TLR6, TLR7, TLR8, CDS, CD68, IL-Ib, IL-6, IL-12, TNF-a and IFNy and (ii) comprises at least one of pseudopeptidoglycans, archaeal lipids, an O-antigens, lipid A, arabinogalactans and beta glucan and at least one different microorganism of the two or more microorganisms comprises at least one of pseudopeptidoglycans, archaeal lipids, an O-antigens, lipid A, arabinogalactans and beta glucan.
- the at least one different microorganism comprises at least one of pseudopeptidoglycans, archaeal lipids, an O-
- a microbial consortium comprising two or more purified or isolated microorganisms, at least one microorganism present at low abundance in a reference human subject being capable of at least one of (i) modulating at least one of TLR2, TLR4, CD8, CD68, IL-Ib, 1L-6, 1L- 12, TNF-a, and IFNy and (ii) comprises at least one of pseudopeptidoglycans, archaeal lipids, an O-antigens, lipid A, arabmogalactans and beta glucan and at least one different microorganism that carries a cell envelope component that is recognized by a subject s immune system.
- the at least one different microorganism may be a microorganism being present at low abundance in a reference human subject or a microorganism being present at high abundance a reference human subject.
- a microbial consortium comprising two or more purified or isolated microorganisms, comprises at least one microorganism present at low abundance in a reference human subject being capable of at least one of (i) modulating at least one of TLR2, TLR4, CD8, CD68, IL-Ib, IL-6, !L-12 TNF-a, and IFNy and (ii) comprises at least one of pseudopeptidoglycans, archaeal lipids, an O-antigens, lipid A, arabmogalactans and beta and at least one different microorganism that comprises at least one of pseudopeptidoglycans, archaeal lipids, an O-antigens, lipid A, arabmogalactans and beta glucan.
- the at least one different microorganism may be a microorganism being present at low abundance in a reference human subject or a microorganism being present at high abundance in
- a microbial consortium comprising two or more purified or isolated microorganisms present at low abundance m a reference human subject being capable of modulating at least one of TLR2, TLR4, CD8, CD68, IL-Ib, IL-6, IL-12 TNF-a and IFNy.
- a microbial consortium comprising two or more purified or isolated microorganisms present at low abundance in a reference human subject being capable of modulating at least one of TLR2, TLR4, CDS, CD68, IL-Ib, IL-6, IL-12 and TNF-a.
- a microbial consortium comprising two or more purified or isolated microorganisms, at least one of the two or more microorganisms having a 16S rDNA sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% identical to at least onel6S rDNA sequence denoted by of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NQ: 3, SEQ ID NO: 4 and SEQ ID NO:.5 and at least one different microorganism of the two or more microorganisms comprises at least one of pseudopeptidoglycans, archaeal lipids, an O- antigens, lipid A, arabinogaiactans and beta glucan.
- the at least one different microorganism may be a microorganism being present at low abundance in a reference human subject or a microorganism being present at high
- a microbial consortium comprising two or more purified or isolated microorganisms, at least one of the two or more microorganisms is present at low abundance in a reference human subject being capable of modulating at least one of TLR2, TLR4, TLR5, TLR6, TLR7, TLR8, CD8, CD68, IL-Ib, IL-6, IL-I2, TNF-a and IFNy and at least one different microorganism of the two or more microorganisms having a 16S rDNA sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% identical to at least one !
- the at least one different microorganism may be a microorganism being present at low abundance in a reference human subject or a microorganism being present at high abundance in a reference human subject.
- wiiich may be implemented as certain embodiments of the microbial consortium of the invention, provided is a microbial consortium comprising two or more purified or isolated microorganisms, at least one of the two or more microorganisms is present at low abundance in a reference human subject being capable of modulating at least one of TLR2, TLR4, CD8, CD68, IL-Ib, IL-6, IL- 12 and TNF-a and at least one different microorganism of the two or more microorganisms having a I6S rDNA sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99 5% identical to at least onel 6S rDNA sequence denoted by of SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
- a microbial consortium comprising two or more purified or isolated microorganisms having a 16S rDNA sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99 5% identical to at least one, at least two, at least three, at least four 16S rDNA sequences listed in Table 1.
- a microbial consortium comprising two or more purified or isolated microorganisms having a 16S rDNA sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% identical to at least one, at least two, at least three, at least fourl 6S rDNA sequence denoted by of SEQ ID NOT , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NQ:5, SEQ ID NQ:6, SEQ ID NO:7 and SEQ ID NO: 8
- a microbial consortium comprising two or more purified or isolated microorganisms having a 16S rDNA sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% identical to one, two, three, four, five, six seven, eight 16S rDNA sequence denoted by of SEQ ID NO: 1, SEQ ID NO: 2.
- the microbial consortium comprises two or more m icroorganisms selected from Methanosphaera stadtmanae DSM3091, Oenococcus oeni PSlJ-1, Clostridium tyrohutyricum KCTC 5387, Cetobacterium somerae ATCC BAA- 474, Corynebacterium glyciniphilum AJ 3170, Bacteroides caccae CL03T12C61, Ruminococcus albus 7, Lactobacillus casei ATCC27139, Veillonella parvula ATCC 17745 and Clostridium cellulovorans 743B.
- the microbial consortium comprises three, at times four, at times five, at times six, at times seven, at times eight, at times nine, at times ten or more microorganisms selected from Methanosphaera stadtmanae DSM3091, Oenococcus oeni PSlJ-1, Clostridium tyrobutyricum KCTC 5387, Cetobacterium somerae ATCC BAA- 474, Corynebacterium glycinipkilum AJ 3170, Bacleroides caccae CL03T12C61, Ruminococcus albus 7, Lactobacillus casei ATCC27139, Veillonella parvula ATCC 17745, Clostridium cellulovorans 743B, Bifidobacterium breve ATCC15700, Alistipes putredini DSM 17216, Akkermansia muciniphila ATCC BAA-835 and Akkermansia muciniphila YL44.
- the microbial consortium comprises at least two isolated or purified microorganisms belonging to the genus, spices or strain identified by NCB1 Taxonomy IDs selected from the group consisting of NCBI Taxonomy ID: 2316, 46254, 180162, 1716, 1485, 2317, 1247, 188913, 1404244, 1519, 1493, 203123, 1 121342, 1319815, 1404245, 573061, 339860, 816, 1263, 1578, 29465, 1678, 239759, 239934, 1264, 1582, 29466, 28117, 1685, 239935, 47678, 686660, 997873, 697329, 518634, 445970, 349741,
- the microbial consortium comprises two or more microorganisms selected from ( denococcus oeni PSU-1, Methanosphaera stadtmanae DSM3091, Clostridium tyrobutyricum KCTC 5387, Cetobacterium. somerae ATCC BAA-474 and Corynebacterium glyciniphilum AJ 3170.
- the microbial consortium comprises two or more microorganisms are selected from Oe nococcus oeni PSU-1 , Methanosphaera stadtmanae DSM3091, Clostridium tyrobutyricum KCTC 5387, and Cetobacterium somerae ATCC BAA-474.
- the microbial consortium consists from Oe nococcus oeni PSU-1, Methanosphaera stadtmanae DSM3091, Clostridium tyrobutyricum KCTC 5387, and Cetobacterium somerae ATCC BAA-474.
- the microbial consortium comprises two or more microorganisms are selected from Oenococcus oeni PSU-1, Methanosphaera stadtmanae DSM3091, Ruminococcus albus 7, Bacteroid.es caccae CL03T 12C61 and Clostridium tyrobutyricum KCTC 5387.
- the microbial consortium comprises two or more microorganisms are selected from Oenococcus oeni PSU-1 , Meihcmosphaera stadirnanae DSM3091, Ruminococcus albus 7 and Bacteroides caccae CL03T12C61.
- the microbial consortium consists from Oenococcus oeni PSV-l, Methanosphaera stadirnanae DSM3Q91, Ruminococcus albus 7 and Bacteroides caccae CL03T12C61.
- the microbial consortium comprises two or more microorganisms are selected from Meihcmosphaera stadirnanae DSM3091, Lactobacillus casei A TCC27139, Veillonella parvula ATCC 17745 and Ruminococcus albus 7.
- the microbial consortium consists from Methanosphaera stadtmanae DSM3091, Ixictobacillus casei A TCC 27139, Veillonella parvula ATCC 17745 and Ruminococcus albus 7.
- the microbial consortium comprises at least one, at least two, at least three and at times, at least all of Corynebacterium glyciniphilum AJ 3170, Cetobacterium somerae ATCC BAA-474, Clostridiu tyrobutyncum KCTC 5387 and Oenococcus oeni PSU-1.
- the microbial consortium comprises Corynebacterium glyciniphilum AJ 3170, Cetobacterium somerae ATCC BAA -474, Clostridium tyrobutyncum KCTC 5387 and Oenococcus oeni PSU-1.
- This microbial consortium comprising the four listed bacterial strains is referred herein as Consortium 1 (“Cons. 1”)
- the microbial consortium comprises at least one, at least two, at least three and at times, at least all of Bacteroides caccae CI.03T12C61 , Clostridium cellulovorans 743B, Lactobacillus casei ATCC27139, Veillonella parvula ATCC 17745.
- the microbial consortium comprises Bacteroides caccae CX03T12C61, Clostridium cellulovorans 743B, IxictobaciUus casei A TCC27139, Veillonella parvula A TCC 17745.
- This microbial consortium comprising the four listed bacterial strains is referred herein as Consortium 2. (“Cons. 2”)
- the microbial consortium comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven and at times, at least all of Corynehacterium glydniphilum AJ 3170, Cetobacteriim somerae ATCC BAA-474, Clostridium tyrobutyricum KCTC 5387, Oenococcus oeni PSU-1, Bacteroides caccae CL03T12C61, Clostridium cellulovorans 743B. Lactobacillus caset ATCC27139 and Veillonella parvula ATCC 17745.
- the microbial consortium comprises Corynehacterium glydniphilum AJ 3170, Cetohactermm somerae ATCC BAA-474, Clostridium tyrobutyricum KCTC 5387, Oenococcus oeni PSU-1, Bacteroides caccae CL03T12C61, Clostridium cellulovorans 743B, Lactobacillus easel ATCC 27139 and Vei!lonel!a parvula ATCC 17745.
- This microbial consortium comprising the eight listed bacterial strains is referred herein as Consortium 3 (“Cons. 3”).
- Consortium 3 includes the microbial strains of both Consortium 1 and Consortium 2.
- the microbial consortium comprises at least one, at least two, at least three, at least all of Cetobacterium somerae ATCC BAA-474, Clostridium tyrobutyricum KCTC 5387, Clostridium cellulovorans 743B and Veillonella parvula ATCC 17745.
- the microbial consortium comprises Cetobacterium somerae ATCC BAA-474, Clostridium tyrobutyricum KCTC 5387, Clostridium cellulovorans 743B and Veillonella parvula ATCC 17745.
- This microbial consortium comprising the four listed bacterial strains is referred herein as Consortium 4 (“Cons. 4”)
- the microbial consortium comprises at least one, at least two, at least three at least all of Cetobacterium somerae A TCC BAA-474, Clostridium tyrobutyricum KCTC 5387, Bacteroides caccae CL03T12C61 and Veillonella parvula ATCC 17745.
- the microbial consortium comprises Cetobacterium somerae A TCC BAA-474, Clostridium tyrobutyricum KCTC 5387, Bacteroides caccae CL03T12C61and Veillonella parvula ATCC 17745.
- This microbial consortium comprising the four listed bacterial strains is referred herein as Consortium 5 (“Cons. 5”).
- microbial consortium of the invention in another aspect of the invention, which may be implemented as certain embodiments of the microbial consortium of the invention, provided is a microbial consortium selected from Consortium 1, Consortium 2, Consortium 3, Consortium 4, and Consortium 5.
- microbial consortium of the invention in another aspect of the invention, which may be implemented as certain embodiments of tire microbial consortium of the invention, provided is a microbial consortium selected from Consortium 1, Consortium 2 and Consortium 3.
- a microbial consortium being at least one of Consortium 1, Consortium 2, Consortium 3, Consortium 4, and Consortium 5
- the microbial consortium comprises the same or equivalent amounts of the microorganisms forming the consortium. In some further embodiments, the microbial consortium comprises different amounts of the microorganisms forming the consortium. In some embodiments, the total number (cell count/amount/ colony forming units-CFUs) of each one of microorganisms forming the microbial consortium is between about 1 X 1 if to about 1 X 10 between 1X10 5 to about 1X10 10 , 1X10 8 to about 5X10 10 , between 2X10 8 to about 4X1Q 10 , between 3X10 8 to about 3X10 10 , between 5X 1G 8 to about 1X10 ! 0 .
- the total number (cell count/amount/ colony forming units- CFUs) of microorganisms forming the microbial consortium is between about 1X10 J to about IX lO 12 , between 1X10 5 to about IXIO i0 , 1X10 8 to about 5X10 10 ,, between 2X10 S to about 4X10 10 , between 3X!G 8 to about 3XIQ 10 , between 5X10 8 to about 1 X1 Q 10 .
- the two or more microorganisms can be identified in or isolated from the microbiome of a reference subject, for example by collecting a biological sample.
- the biological sample may be any sample from which the population of microorganisms can be isolated, for example, faeces.
- the sample may be a biopsy of human organs or tissue, specifically, a gut biopsy.
- the microbial consortium may be formulated in a variety of forms, depending on the storage, administration etc. Non-limiting forms include solid, dry form, for example, in a lyophi!ized powder, gel form, a suspension, a cell lysate or extract. In some embodiments, the microbial consortium may be suspended in a liquid medium (such as PBS or saline) and used in a suspension form.
- a liquid medium such as PBS or saline
- the microbial consortium of the invention may be used in the preparation of a pharmaceutical formulation/compositions/suspension or in the manufacture of a formulation/compositions/suspension for use in treatment.
- formulation/compositions/suspension of the invention may comprise apart from a therapeutically effective amount of a microbial consortium of the invention, at least one additional components as detailed herein.
- the invention relates to a composition (suspension or formulation) comprising microbial consortium of the invention.
- the nucrobial consortium and/or the suspension/composition comprising the same may form a kit of the invention.
- the composition and/or the suspension and/or kit described herein comprising the microbial consortium as well as the microbial consortium per se form part of this invention. It should be noted that the forms described herein for the microbial consortium per se apply for the composition and/or the suspension and/or kit comprising the microbial consortium.
- composition of the invention may optionally further comprise at least one of pharmaceutically acceptable carrier/s, excipient/s, additive/s diluent/s and adjuvant's.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings and the like.
- Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran.
- the suspension may also contain stabilizers.
- formulations may also include other agents conventional in the art having regard to the type of formulation in question.
- the microbial consortium of the invention and/or any suspensions/compositions comprising die same can be administered and dosed by the methods of the invention as described below, in accordance with medical procedures known in the art.
- the suspensions/compositions used in the methods and kits of the invention, described herein below may be adapted for administration by various modes of interferon administration are known in the art. These include, but are not limited to, injection (e.g., using a subcutaneous, intramuscular, intravenous, or intrademial injection), intranasal administration and oral administration.
- the microbial consortium of the invention and/or any suspensions/compositions comprising the same may be formulated for oral administration.
- the microbial consortium of the invention and/or any suspensions/compositions comprising the same may be formulated for delivery to the intestine. In some embodiments, the microbial consortium of the invention and/or any suspensions/compositions comprising the same may be formulated into food or a beverage.
- the microbial consortium of the invention and/or any suspensions/compositions comprising the same may be formulated to be contained within a earner.
- the microbial consortium of the invention and/or any suspensions/compositions comprising the same is enterically coated.
- the microbial consortium, the compositions comprising the microbial consortium of the present invention and the kits of the invention may be useful for a variety of purposes, such as in the treatment of subjects in need of a treatment by the microbial consortium of the invention. Specifically, by affecting the immune system of a host subject, treatment of, for example, a proliferative disorder may be achieved.
- the microbial consortium as well as compositions and kits of the invention may be administered to a human subject for the treatment of proliferative disorder such as cancer.
- proliferative disorder such as cancer.
- the microbial consortiums of the invention were capable of inhibiting tumor growth.
- the present invention further provides a m icrobial consortium according to the invention comprising two or more purified or isolated microorganisms of the invention, the compositions comprising the same or kits of the invention for use in a method of treating of a subject suffering from a proliferative disorder.
- the microbial consortium is for use in treating a subject being diagnosed with a disease that may be treatable by the microbial consortium as detailed herein, such as a proliferative disorder.
- a proliferative disorder is a disorder displaying ceil division and growth that is not part of normal cellular turnover, metabolism, growth, or propagation of the whole organism. Unwanted proliferation of cells is seen in tumors and other pathological proliferation of cells, does not serve normal function, and for the most part will continue unbridled at a growth rate exceeding that of cells of a normal tissue in the absence of outside intervention. A pathological state that ensues because of the unwanted proliferation of cells is referred herein as a "hyper-proliferative disease” or "hyper- proliferative disorder.”
- Non-limiting examples of proliferative disorder include cancer, atherosclerosis, rheumatoid arthritis, psoriasis, idiopathic pulmonary' fibrosis, scleroderma and Cirrhosis of the liver.
- the microbial consortium of the inventi on comprising two or more purified or isolated microorganisms, the compositions comprising the same and kits of the invention are for use in treating cancer.
- cancer As used herein to describe the present invention, “cancer”, “tumor” and “malignancy” all relate equivalently to a hyperplasia of a tissue or organ.
- the microbial consortium composition or kits comprising the same of the invention may be used in methods of the invention for the treatment of any one of non-solid tumor and solid tumors.
- Non-limiting examples of cancers include blastoma, carcinoma, lymphoma, leukemia, sarcoma, mesothelioma, glioma, germinoma, choriocarcinoma, skin cancer (such as basal-cell skin cancer (BCC), squamous-cell skin cancer (SCC) melanoma), glioblastoma, lymphoid malignancies, squamous cell cancer (e.g.
- lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer.
- lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer,
- the cancer is a solid cancer type or a hematologic cancer type.
- the cancer is a solid cancer.
- solid cancer refers to a solid tumor is an abnormal mass of tissue that usually does not contain cysts or liquid areas and that is malignant. Examples of solid tumors are sarcomas, carcinomas, and lymphomas.
- the cancer is a hematologic cancer (also denoted as blood cancer).
- Hematologic cancer typically begins in blood-forming tissue, such as the bone marrow', or in the cells of the immune system. Examples of hematologic cancer are leukemia, lymphoma, and multiple myeloma.
- the cancer is at least one of breast cancer, lung cancer, ovarian cancer prostate cancer, liver cancer, pancreatic cancer, bladder cancer, prostate cancer, cancer of the uterine cervix, brain cancer, colon cancer, gastrointestinal cancer, skin cancer such as melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and lymphomas.
- the cancer is a skin cancer. In some embodiments, the cancer is melanoma.
- the cancer is at least one of breast cancer, lung cancer, pancreatic cancer, bladder cancer, melanoma, kidney cancer, prostate cancer, head and neck cancer, and lymphoma.
- the cancer is selected from breast cancer, lung cancer, melanoma and kidney cancer.
- the cancer is selected from breast cancer and melanoma.
- the cancer is breast cancer. In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is a non-small cell lung cancer (NSCLC).
- NSCLC non-small cell lung cancer
- the cancer is kidney cancer. In some embodiments, the cancer is Renal Cell Carcinoma (RCC).
- RRC Renal Cell Carcinoma
- the cancer is bladder cancer.
- the cancer is prostate cancer.
- the cancer is pancreatic cancer.
- the cancer is head and neck cancer.
- the cancer is lymphoma.
- the microbial consortium of the invention comprising two or more purified or isolated microorganisms is administrated in combination with an additional treatment.
- the microbial consortium of the present invention were superior over anti PD-1 inhibitor alone in their ability to inhibit tumor growth as well as in their ability to modulate the activity, expression and secretion of pro-inflammatory cytokines and cluster of differentiation molecules.
- treatment with the microbial consortium of the present invention induced an increased secretion of plasma cytokines, INFg, IL6, IL12 and an increased expression of CD8 and CD68 as compared to treatment with anti PD-1 alone.
- the microbial consortium of the present invention may be used as for treatment alone or as an adjuvant therapy, specifically for treating cancer.
- the microbial consortium may be administered in simultaneously or sequentially with an anticancer treatment.
- the microbial consortium may be administered concurrently with an anticancer treatment.
- Both the microbial consortium and the anticancer treatment may be administered any administration method and route commonly known and/or used in the field, which may be the same or different for the two.
- an anti -cancer agent and/or anti -cancer treatment include chemotherapy, radiation therapy, surgical therapy, a receptor kinase inhibitor (such as tyrosine), an immune checkpoint inhibitor or any other targeted cancer therapy, an immunotherapy agent, a hormone agent, a biological agent, cytokine agent, a differentiation factor, an anti -angiogenic factor, CAR T-cell therapy or any other cell- based therapy, or an immune -modulatory'.
- the anticancer treatment is an anticancer agent.
- the anticancer treatment is a receptor kinase inhibitor (such as tyrosine), an immune checkpoint inhibitor or any other targeted cancer therapy, an immunotherapy agent, a hormone agent, a biological agent, cytokine agent, a differentiation factor, an anti-angiogenic factor, CAR T-cell therapy or any other cell- based therapy, or an immune-stimulator ⁇ '
- the anticancer treatment is an immune checkpoint inhibitor.
- An immune checkpoint inhibitor typically block certain proteins made by some types of immune system cells, such as T cells, and some cancer cells.
- checkpoint proteins found on T cells or cancer cells include, for example, PD-1/PD-L1 and CTLA-4/B7-1/B7-2
- a checkpoint inhibitor may be an immunotherapy agent such as for example a monoclonal antibody.
- tire anticancer treatment is a checkpoint inhibitor selected from an anti- PD-1 inhibitor, an anti-CTLA-4 inhibitor, an anti-PD-Ll inhibitor or combinations thereof.
- the inhibitor may be a small molecule, an antibody, an aptarner, an oligomer, a polymer.
- the checkpoint inhibitor selected from an anti- PD-1 antibody, an anti-CTLA-4 antibody, an anti-PD-Ll antibody or combinations thereof.
- the checkpoint inhibitor is at least one of Ipilimumab, Nivoiumah, Pembrolizumab, Atezolizumab, Ave!umab, Durvalumab and Cemiplimab or any combinations thereof.
- the checkpoint inhibitor is an anti- PD-1 inhibitor.
- the checkpoint inhibitor is Pembrolizumab.
- the microbial consortium of the invention reduces the rate of tumor growth. Hence, it was suggested that the microbial consortium of the invention can be used in method of inhibiting cancer growth and hence in cancer treatment.
- the invention provides a method for treating a disorder in a subject in need thereof.
- the method for treating, preventing, ameliorating, reducing or delaying the onset of a proliferative disorder in a subject in need thereof comprising administering to such subject a therapeutically effective amount of a microbial consortium of the invention or any composition or kit comprising the same.
- administering the effective amount of a microbial consortium of the invention ameliorates one or more signs or symptoms of the proliferative disorder, such as cancer.
- the methods of the invention are for treating disorders may be treatable with the microbial consortium of the invention.
- the invention provides a method of treating, preventing, ameliorating, reducing or delaying the onset of a proliferative disorder, such as cancer, in a human subject in need thereof comprising the step of administering to the subject an effective amount of a microbial consortium comprising two or more isolated microorganism or purified microorganism, at least one of the two or more microorganisms is present at low-abundance in a microbiome of a reference human subject.
- the microbial consortium comprises at least one other of the two or more microorganisms hav ing at least one of (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (ill) comprises at least one cell envelope component being recognized by the human subject s immune system or an epithelial cell, such as intestinal epithelial cell.
- the invention provides a method of treating, preventing, ameliorating, reducing or delaying the onset of a proliferative disorder, such as cancer, m a human subject in need thereof comprising the step of administering to the subject an effective amount of a microbial consortium comprising two or more isolated microorganism or purified microorganism, at least one of the two or more microorganisms is present at low-abundance m a microbiome of a reference human subject and having at least one (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component being recognized by the human subject ’ s immune system or an epithelial cell, such as intestinal epithelial cell.
- the methods of the invention comprises administration of a therapeutically effective amount of a microbial consortium comprises 16S rRNA sequences having at least at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% identity with nucleic acid sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NQ:3, SEQ ID NO: 4 and SEQ ID NO: 5
- the methods of the invention comprises administration of a therapeutically effective amount of a microbial consortium comprises one, two, three, four or five microorganisms selected from Oenococcus oeni PSU-1, Clostridium iyrobutyricum KCTC 5387, Cetobacterium some me ATCC BAA-474, Corynebacterium glyciniphilum AJ 3170, and Clostridiu cellulovorans 743B.
- the methods of the invention comprises administration of a therapeutically effective amount of a microbial consortium comprises at least one microorganism, at least two microorganisms, at least three microorganisms from the Bacteroides caccae species Lactobacillus casei species or Veillonella parvula species.
- the methods of the in vention comprises administration of a therapeutically effective amount of a microbial consortium comprises at least one microorganism comprises 16S rRNA sequences having between 85% to 99%, at times between 90% to 99%, at times between 95% to 99%, at times between 96% to 99%, at times between 97% to 99%, at times between 98% to 99% identity with nucleic acid sequences selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO: 9
- the methods of the invention comprises administration of a therapeutically effective amount of a microbial consortium comprises at least one, at least two of Bacteroides caccae CL03T12C61, Lactobacillus casei ATCC 27139 or Veillonella parvula ATCC 17745.
- the methods of the invention comprises administration to the subject a therapeutically effective amount of a microbial consortium comprising two or more purified or isolated microorganisms having a 16S rDNA sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99 5% identical to one, two, three, four, five, six seven, eight 16S rDNA sequence listed in Table 1.
- the methods of the invention comprises administration to the subject a therapeutically effective amount of a microbial consortium comprising two or more purified or isolated microorganisms having a 16S rDNA sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99 5% identical to one, two, three, four, five, six seven, eight 16S rDNA sequence denoted by of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 5 SEQ ID NO:6, SEQ ID NO: 7 and SEQ ID NON.
- the methods of the invention comprises administration to the subject a therapeutically effective amount of a microbial consortium being at least one of Consortium 1, Consortium 2, Consortium 3, Consortium 4, and Consortium 5.
- a method for treating, pre venting, ameliorating, reducing or delaying the onset of a proliferative disorder, such as cancer, in a human subject in need thereof comprising administration a therapeutically effective amount of the microbial consortium of the invention with a therapeutically effective amount of an anticancer treatment.
- the method comprising administrating to the subject a therapeutically effective amount of the microbial consortium of the invention and a therapeutically effective amount of the anticancer treatment simultaneously or sequentially.
- the method comprising administrating to the subject a therapeutically effective amount of the microbial consortium of the invention and a therapeutically effective amount of the anticancer treatment concurrently.
- the methods of the invention for treating, preventing, ameliorating, reducing or delaying the onset of cancer comprising administrating to the subject in need thereof a therapeutically effective amount of the microbial consortium of the invention and a therapeutically effective amount of the anticancer treatment, the method comprising administrating a therapeutically effective amount of the microbial consortium with a therapeutically effective amount of a checkpoint inhibitor as detailed herein.
- the cancer is at least one of breast cancer, lung cancer, ovarian cancer prostate cancer, liver cancer, pancreatic cancer, bladder cancer, prostate cancer, cancer of the uterine cervix, skin cancer (such as melanoma), brain cancer, colon cancer, gastrointestinal cancer, melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and lymphomas.
- skin cancer such as melanoma
- brain cancer colon cancer
- gastrointestinal cancer melanoma
- melanoma lung cancer
- kidney cancer kidney cancer
- bladder cancer head and neck cancer
- lymphomas lymphomas
- the cancer is at least one of breast cancer, lung cancer, pancreatic cancer, bladder cancer, melanoma, kidney cancer, prostate cancer, head and neck cancer, and lymphoma.
- the cancer is selected from breast cancer, lung cancer, melanoma and kidney cancer.
- the cancer is selected from breast cancer and melanoma.
- the cancer is a skin cancer. In some embodiments, the cancer is melanoma.
- the cancer is breast cancer.
- the cancer is lung cancer. In some embodiments, the cancer is a non-small cell lung cancer (NSCLC)
- NSCLC non-small cell lung cancer
- the cancer is kidney cancer. In some embodiments, the cancer is Renal Cell Carcinoma (RCC).
- RRC Renal Cell Carcinoma
- the cancer is bladder cancer.
- the cancer is prostate cancer.
- the cancer is pancreatic cancer.
- the cancer is head and neck cancer.
- the cancer is lymphoma.
- the microbial consortium may be administrated to a human subject by any method known in the art and described herein.
- the methods of the invention comprise administration the microbial consortium or a composition comprising the microbial consortium by oral administration.
- the methods of the invention comprise administration the microbial consortium or a composition comprising the microbial consortium that is formulated for deliver ⁇ ' to the intestine.
- the microbial consortium or a composition comprising the microbial consortium may be formulated for example into a capsule, tablet, food or beverage or any of the like.
- the methods of the invention may compri se administrating the microbial consortium of the invention, compositions or kits comprising the same and optionally an additional treatment, as a single one-time dose, as a single daily dose or multiple daily doses, preferably, ever 1 to 7 days. It is specifically contemplated that such application may be carried out once or several times in the lifetime of a patien t, once, twice, thrice, four times, five times or six times daily, or may be performed once daily, once ever ⁇ ' 2 days, once ever ⁇ ' 3 days, once every 4 days, once every 5 days, once every 6 days, once every week, two weeks, three weeks, four weeks or even more than a month.
- the invention further provides the use of a microbial consortium of the invention in the preparation of a composition for treating a proliferative disorder in a subject in need thereof.
- a use of a microbial consortium comprising two or more microorganisms, at least one of the two or more microorganisms is present at low- abundance in a microbiome of a reference human subject and at least one other of the two or more microorganisms having at least one of (i) capable of modulating at least one short chain fatty acid (SCFA), (ii) capable of modulating lactate and (hi) comprises at least one cell envelope component in the preparation of a composition for treating a proliferative disorder in a subject in need thereof.
- SCFA short chain fatty acid
- lactate capable of modulating lactate
- hi comprises at least one cell envelope component in the preparation of a composition for treating a proliferative disorder in a subject in need thereof.
- the invention further provides the use of a microbial consortium of the invention in the preparation of a composition for treating a proliferative disorder in a subj ect in need thereof.
- a use of a microbial consortium comprising two or more microorganisms, at least one of the two or more microorganisms is present at low- abundance in a microbiome of a reference human subject and having at least one (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component in the preparation of a composition for treating a proliferative disorder in a subject in need thereof.
- the invention provides a kit comprising microbial consortium of the invention in the preparation of a composition for treating a proliferative disorder in a subject in need thereof.
- a microbial consortium comprising two or more microorganisms, at least one of the two or more microorganisms is present at low-abundance in a microbiome of a reference human subject and at least one other of the two or more microorganisms having at least one of (i) capable of modulating at least one short chain fatty acid (SCFA), (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component.
- SCFA short chain fatty acid
- the invention provides a kit comprising microbial consortium of the invention in the preparation of a composition for treating a proliferative disorder in a subject in need thereof.
- a microbial consortium comprising two or more microorganisms, at least one of the two or more microorganisms is present at low-abundance in a microbiome of a reference human subject and having at least one (i) capable of modulating at least one SCFA, (ii) capable of modulating lactate and (iii) comprises at least one cell envelope component.
- kits described herein may include a composition/suspension as described, as an already prepared dosage form ready for administration or, alternatively, can include the microbial consortium or a composition comprising the microbial consortium as described as a solid pharmaceutical composition (e.g. in a !yophiiized form) that can be reconstituted with a solvent to provide a liquid dosage form.
- the kit of the invention may additionally comprise instructions for using the kit in treating a proliferative disorder.
- the methods of treatment provided herein involve administration of the microbial consortium of the invention in a therapeutically effective amount.
- effective amount is that determined by such considerations as are known to the man of skill in the art.
- the present invention provides methods for treating or preventing a proliferative disorder.
- treatment or prevention refers to the complete range of therapeutically positive effects of administrating to a subject including inhibition, reduction of, alleviation of, and relief from, proliferative disorder symptoms or undesired side effects of such proliferative disorder related disorders.
- the present invention relates to methods for tire treatment of subjects, or patients, in need thereof.
- patient or“subject in need” it is meant any organism who may be affected by the above-mentioned conditions, and to whom the treatment methods herein described are desired.
- administering of the compositions of the invention to the patient includes both self administration and administration to the patient by another person.
- the invention provides methods for treating proliferative disorders, and further relates to disorders associated or related to cancer.
- associated and “related”, when referring to pathologies herein, mean diseases, disorders, conditions, or any pathologies which at least one of: share causalities, co-exist at a higher than coincidental frequency, or where at least one disease, disorder condition or pathology causes the second disease, disorder, condition or pathology.
- such increase or enhancement may be an increase or elevation of between about 5% to 100%, specifically, 10% to 100% of the activity as compared to a suitable control for example being no treatment, for example with no stimulant (no microorganisms, denoted herein as -LPS) or without an additional anticancer drug, such as without an anti -PD 1 , or in the absence of the microbiome consortium of the invention of the invention.
- a suitable control for example being no treatment, for example with no stimulant (no microorganisms, denoted herein as -LPS) or without an additional anticancer drug, such as without an anti -PD 1 , or in the absence of the microbiome consortium of the invention of the invention.
- TLR Toll-like receptors
- the objective of this study was to evaluate TLR activation following incubation with various bacterial strains, using InvivoGen’s HEK-BlueTM TLR cells (derived from HEK293 cells) and secreted alkaline phosphatase (SEAP) reporter system.
- HEK-BlueTM TLR2 and HEK-BlueTM TLR4 cells were incubated with escalating concentrations of various bacterial strains (bacteriaicell ratios 1 :2.78, 1 :8.33, 1:5) for 20 hours at 37°C, 5% CO2.
- TLR activation was measured as SEAP secretion and quantified using colorimetric reader in 630nm OD, as follows, TLR2 and TLR4 ligands activate NF- KB and AP-1 which induce the production of SEAP HEK-BlueTM Detection cell culture medium allows the detection of SEAP as a readout of TLR activation.
- Example IB Cytokines secretion in macrophage cells lines
- Hie objective of this study was to evaluate the efficacy of various bacterial strains and combinations of bacterial strains in stimulating cytokines’ secretion from RAW murine macrophages cell lines, compared to Lipopolysaceharide (LPS) stimulation.
- LPS Lipopolysaceharide
- RAW cells were incubated with various bacterial strains (iO 8 CFU/ml) for 16 hours at 37°C, 5% CO2 Hie medium (supernatant) was collected and analyzed for cytokines secretion by R&D DouSet ELISA development systems according to manufacturer’s protocol. Each bacteria was tested in triplicates.
- Figs. 3A ⁇ 3C show that Cetobacterium somerae ATCC BAA-474 induced the largest secretion of TNFa and IL6 and Fig. 3C shows that Veillonella parvula A TCC 17745, followed by Cetobacterium somerae ATCC BAA -474 induced the largest secretion of ILlb.
- Figs. 4A to 4C show' the effect of bacterial combinations in inducing secretion of cytokines. Specifically, the following five combinations (consortiums) were tested:
- Cons. 1 includes Corynebacterium glycimphilum AJ 3170, Cetobacterium somerae ATCC BAA-474, Clostridium tyrobutyricum KCTC 5387 and Oenococcus oeni PSU-1;
- Cons. 2 comprises Bacteroides caccae CL03T12C61, Clostridium cellulovorans 743B, Lactobacillus casei ATCC27139, Veillonella parvula ATCC 17745;
- Consortium 3 (“Cons. 3”) comprises Corynebacterium glycimphilum AJ 3170, Cetobacterium somerae ATCC BAA-474, Clostridium tyrobutyricum KCTC 5387, Oenococcus oeni PSU-1, Bacteroides caccae CL03T12C61, Clostridium cellulovorans 743B, Lactobacillus casei ATCC27139 and Veillonella parvula ATCC 17745; Consortium 4 ('‘Cons. 4”) comprises Cetobacterium somerae ATCC BAA-474, Clostridium tyrobutyricum KCTC 5387, Clostridium cellulovorans 743B and Veillonella parvula ATCC 17745;
- Consortium 5 (“Cons. 5"’) comprises Cetobacterium somerae ATCC BAA-474, Clostridium tyrobutyricum KCTC 5387, Bacteroides caccae CL03T12C61and Veillonella parvula ATCC 17745.
- Figs. 4A to 4C show that all the tested bacterial consortiums induced secretion of cytokines suggesting that combination of the identified bacterial strains are effective in modulating proinf!ammatory response. This may suggests an additive effect of the bacterial strains in each consortium.
- Example 1C Cytokines secretion from human peripheral blood mononuclear cell (PBMCs)
- the objective of this study was to evaluate the efficacy of various bacterial strains and combinations of bacterial strains in stimulating cytokines’ secretion from PBMC, compared to Lipopolysaccharide (LPS) stimulation.
- LPS Lipopolysaccharide
- Human Venous blood ( 10-15 mL) was collected into heparinized vials and mixed well by gently inverting the tube several times.
- the blood was diluted x2 with PBS.
- Histopaque was added to a 50 mL centrifuge tube in half of the final blood: PBS volume.
- the blood was gently layered on the top of Histopaque using a 1 ml. auto pipette. The layering was done very slowly so that blood and Histopaque stayed as two different layers.
- Hie tubes were centrifuged (without any delay) at 400 x g for 30 min at +20°C in a swing-out bucket without break.
- PBMCs whitish buffy coat
- PBMCs peripheral blood mononuclear cells
- Figs. 5A-5B are bar graphs showing the efficacy of bacterial strains in stimulating cytokines’ secretion from PBMCs, IL6 (Fig. 5A), TNFa (Fig. SB). As can be seen, most of the bacterial strains including the low abundance bacterial strains stimulated secretion from the cells in an increased level as compared with LPS secretion.
- the in vitro results show the ability of the bacterial strains as well as the combination of two or more bacterial strains to increase the signal of pro-inflammatory response both from macrophages and from PBMC.
- the low abundance bacterial strains were capable of activating the pro- inflammatory response as good or even to a higher extend compared with the high abundance bacterial strains suggesting that although these bacterial strains are present in the microbiome at low abundance, they have the potential to activate an inflammatory' response in the host.
- This type of inflammatory response is suggested to suppress and limit tumor growth.
- the objective of the study was to determine tire efficacy of bacterial consortia treatment combination with anti PD-I treatment (Anti-Mouse PD-1 (CD279), which is the equivalent of pembrolizumab for use in murine) on the development of E0771 derived breast cancer tumors in C57BL/6 female mice.
- Anti-Mouse PD-1 CD279
- mice were injected into their right flank with 1.5xl0 5 E0771 cells in 50 m ⁇ PBS:Matrigel (1 : 1). Tumor volume was measured from Day 5 and twice a week thereafter until study termination. In addition, on Day 1 the mice started receiving antibiotics cocktail (Ampicillin ( 1 g/L), Neomycin (1 g/L), Metronidazole ( 1 g/L) and Vancomycin (0.5 g/L)) in their drinking water. Antibiotics were administered until and including Day 13. On Day 14 of the study the water and water bottles were changed to water without antibiotics.
- antibiotics cocktail Amicillin ( 1 g/L)
- Neomycin 1 g/L
- Metronidazole 1 g/L
- Vancomycin 0.5 g/L
- mice were allocated into five groups of 10 or 15 mice, with similar mean tumor volume.
- the first oral treatment was administered 24 hours after cessation of antibiotics; the bacterial consortia were administered by oral gavage and anti- PD1 by intraperitoneally administration.
- mice received another seven oral gavages of bacteria (2 gavages per week) and anti-PDl or only anti -PD 1.
- Cons. 1 includes Coryne bacterium glyciniphilum AJ 3170, Cetobacterium somerae ATCC BAA-474, Clostridium tyrohutyricum KCTC 5387 and Oenococcus oeni PSTJ-1;
- Cons. 2 (“Cons. 2”) comprises Bacteroides caccae CL03T12C61, Clostridium celhdovorans 743B , Lactobacillus casei ATCC27139, Veillonella parvula ATCC 17745 ;
- Cons. 3 (“Cons. 3”) comprises Corynebacterium glyciniphilum AJ 3170, Cetobacterium somerae ATCC BAA-474, Clostridium tyrohutyricum KCTC 5387, Oenococcus oeni PSU-1, Bacteroides caccae CL03T12C61, Clostridium celhdovorans 743B, Lactobacillus casei ATCC27139 and Veillonella parvula ATCC 17745.
- Tumors were measured for length (L) and width (W) using a digital caliper starting from tumor appearance (around 4 days after cell inoculation) and twice a week thereafter. Tumor volume (in mm 3 ) was calculated according to the equation (i . W’ 0.5).
- Thl cytokine panel was evaluated on plasma samples (IFFvy, IL-6 and IL-12) taken at the day of termination of each animal.
- tumors were excised and placed in formalin and further processed for histopaihoiogical evaluation. Paraffin-embedded 4mpi section of the tumors were stained with H&E and examined for inflammation parameters and infiltration of lymphocytes that were graded by an acceptable grading system. In addition, immunohistochemistry (IHC) analyses was performed to detect CD8 and CD68 expression using specific antibodies.
- IHC immunohistochemistry
- the IHC (immunohistochemistry) scoring grade (CD8, CD68) was held performed on a scale of 0 to 4:
- Fig. 6 A shows a reduction in tumor volume for all the three bacterial strains combinations administrated with anti -PD 1 as compared to untreated mice.
- Fig. 6A show' that all the three bacterial strains combinations administrated with anti -PD 1 w'ere more effective in reducing tumor volume in comparison with anti-PDl alone.
- the effect of consortium 1 with anti- PD1 and consortium 2 with anti-PDl was observed at later time points. This may be attributed for example to the time period required for colonialization of the bacterial strains combinations and activation of the host immune system by the bacterial strains combinations.
- Fig. 6A show' that the effect on tumor volume of consortium 3 that comprise 8 bacterial strains with anti-PDl was more significant and was observed at an earlier time point as compared to consortium 1 with anti-PDl and consortium 2 with anti- PDl
- cytokines in the plasma of the mice showed that the combination of the bacterial strains an anti PD-1 induced an increased secretion of plasma cytokines, INFy, (Fig. 6C), IL6 (Fig. 6D), IL12 (Fig. 6E) as compared to mice treated with anti PD-1 alone.
- the objective of the study is to determine the efficacy of bacterial consortia treatment in combination with anti PD-1 treatment on the development of EO771 derived breast cancer tumors in C57BL/6 female mice.
- mice are injected into their right flank with 1.5x10’ E0771 cells in 50 mT PBS:Matrigel (1 : 1 ). Tumor volume is measured from Day 5 and twice a week thereafter until study termination. In addition, on Day 1 the mice receive antibiotics cocktail (Ampiciliin (I g/L), Neomycin ( 1 g/L), Metronidazole (1 g/L) and Vancomycin (0.5 g/L)) in their drinking water. Antibiotics are administered until and including Day 13. On Day 14 of the study the water and water bottles are changed to water without antibiotics.
- antibiotics cocktail Ampliiciliin (I g/L)
- Neomycin 1 g/L
- Metronidazole 1 g/L
- Vancomycin 0.5 g/L
- mice are allocated into groups of 10 or 15 mice, with similar mean tumor volume.
- the first oral treatment is administered 24 hours after cessation of antibiotics; the bacterial consortia are administered by oral gavage and anti-PDl by i.p administration.
- mice receive another seven oral gavages of bacteria (2 gavages per week) and anti -PD 1 or only anti -PD 1.
- Cons. 5 comprises Cetobacteriurn somerae ATCC BAA-474, Clostridium tyrobuiyricum KCTC 5387, Bacteroides caccae CL03T12C61and Veillonella parvula ATCC 17745.
- Tumors are measured for length (L) and width (W) using a digital caliper starting from tumor appearance (around 4 days after cell inoculation) and twice a week thereafter. Tumor volume (in mm 3 ) is calculated according to the equation (LxW 2 xQ.5).
- Thl cytokine panel is evaluated on plasma samples (IFNy, IL-6 and IL-12) taken at the day of termination of each animal.
- tumors are excised and placed in formalin and are further process for histopathological evaluation .
- Paraffin-embedded 4mhi section of the tumors are stained with H&E and are examine for inflammation parameters and infiltration of lymphocytes that are graded by an acceptable grading system .
- immunohistochemistry (IHC) analyses is performed to detect CD8 and CD68 expression using specific antibodies.
- the objective of the study is to determine the efficacy of bacterial consortia treatment in combination with anti PD-1 treatment on the development of melanoma tumors in C57BL/6 mice.
- mice On study‘Day G ⁇ mice are injected into their right flank with 1.5x10 s BRAF O cells in 50 m ⁇ , PBS:Matrigel (1: 1). Tumor volume is measured from Day 5 and twice a week thereafter until study termination. In addition, on Day 1 the mice receive antibiotics cocktail (Ampicillin (1 g/L), Neomycin ( 1 g/L), Metronidazole ( 1 g/L) and Vancomycin (0.5 g/L)) in their drinking water. Antibiotics are administered until and including Day 13. On Day 14 of the study the water and water bottles are changed to water without antibiotics.
- antibiotics cocktail Amicillin (1 g/L)
- Neomycin 1 g/L
- Metronidazole 1 g/L
- Vancomycin 0.5 g/L
- mice are allocated into groups of 10 or 15 mice, with similar mean tumor volume.
- the first oral treatment is administered 24 hours after cessation of antibiotics; the bacterial consortia are administered by oral gavage and anti-PDl by i.p administration.
- mice are administered with one of these treatments; (1) anti-PDl , (2) Cons. 1+ anti-PDl, (3) Cons. 2+ anti-PDl or (4) Cons. 3+ anti-PDl, (5) Cons. 4+ anti-PDl , (6) Cons 5+ anti-PDl (7)
- PBS administrated via oral gavage at similar volume that is used to administer bacterial consortia as control group.
- mice receive another seven oral gavages of bacteria (2 gavages per week) and anti-PD 1 or only anti -PD 1.
- Consortium 1 (“Cons. 1”) includes Corynebacterium glyciniphihm AJ 3170, Cetobacterium somerae ATCC BAA-474, Clostridium tyrobutyricum KCTC 5387 and Oenococcus oeni PSU-1;
- Cons. 2 comprises Bacteroides caccae CL03T12C61, Clostridium cellulovorans 743B, Lactobacillus casei ATCC27139, Veillonella parvula A TCC 17745 ;
- Cons. 3 (“Cons. 3”) comprises Corynebacterium glyciniphilum AI 3170, Cetobacterium somerae ATCC BAA -474, Clostridium tyrobutyricum KCTC 5387, Oenococcus oeni PSU-1, Bacteroides caccae CL03TI2C61, Clostridium cellulovorans 743B , Lactobacillus casei ATCC27139 and Veillonella parvula ATCC 17745.
- Cons. 5 comprises Cetobacterium somerae ATCC BAA-474, Clostridium tyrobutyricum KCTC 5387, Bacteroides caccae CL03T12C61and Veillonella parvula ATCC 17745.
- Tumors are measured for length (L) and width (W) using a digital caliper starting from tumor appearance (around 4 days after cell inoculation) and twice a week thereafter. Tumor volume (in mm 3 ) is calculated according to the equation (LxW 2 xQ.5).
- Thl cytokine panel is evaluated on plasma samples (IFNy, IL-6 and IL-12) taken at the day of termination of each animal.
- tumors are excised and are placed in formalin and are further processed for histopathological evaluation.
- Paraffin-embedded 4mih section of the tumors are stained with H&E and are examined for inflammation parameters and infiltration of lymphocytes that are graded by an acceptable grading system.
- immunohistochemistry (1HC) analyses is performed to detect CDS and CD68 expression using specific antibodies.
- the IHC (immunohistochemistry) scoring grade ) CD8, CD68) is held performed on a scale of 0 to 4:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021560473A JP2022528960A (en) | 2019-03-31 | 2020-03-31 | Microbial consortium and its use |
CA3132113A CA3132113A1 (en) | 2019-03-31 | 2020-03-31 | Microbial consortium and uses thereof |
CN202080036908.1A CN113840616A (en) | 2019-03-31 | 2020-03-31 | Microbial consortia and uses thereof |
AU2020254126A AU2020254126A1 (en) | 2019-03-31 | 2020-03-31 | Microbial consortium and uses thereof |
EP20782777.5A EP3946391A4 (en) | 2019-03-31 | 2020-03-31 | Microbial consortium and uses thereof |
KR1020217034866A KR20220004983A (en) | 2019-03-31 | 2020-03-31 | Microbial consortium and uses thereof |
US17/601,619 US20220202883A1 (en) | 2019-03-31 | 2020-03-31 | Microbial consortium and uses thereof |
IL286769A IL286769A (en) | 2019-03-31 | 2021-09-29 | Microbial consortium and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL265735 | 2019-03-31 | ||
IL265735A IL265735A (en) | 2019-03-31 | 2019-03-31 | Microbial consortium and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020202148A1 true WO2020202148A1 (en) | 2020-10-08 |
Family
ID=66768857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2020/050389 WO2020202148A1 (en) | 2019-03-31 | 2020-03-31 | Microbial consortium and uses thereof |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220202883A1 (en) |
EP (1) | EP3946391A4 (en) |
JP (1) | JP2022528960A (en) |
KR (1) | KR20220004983A (en) |
CN (1) | CN113840616A (en) |
AU (1) | AU2020254126A1 (en) |
CA (1) | CA3132113A1 (en) |
IL (2) | IL265735A (en) |
WO (1) | WO2020202148A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024028479A1 (en) * | 2022-08-05 | 2024-02-08 | Universite Catholique De Louvain | Dysosmobacter for the treatment of breast cancer |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL308253A (en) * | 2021-05-12 | 2024-01-01 | Biomica Ltd | Microbial consortium and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1917869A1 (en) * | 2006-09-19 | 2008-05-07 | National Starch and Chemical Investment Holding Corporation | Probiotic/non-probiotic combinations |
WO2016086205A2 (en) * | 2014-11-25 | 2016-06-02 | Epiva Biosciences, Inc. | Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome |
US20160354416A1 (en) * | 2015-06-01 | 2016-12-08 | The University Of Chicago | Treatment of cancer by manipulation of commensal microflora |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201520631D0 (en) * | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
-
2019
- 2019-03-31 IL IL265735A patent/IL265735A/en unknown
-
2020
- 2020-03-31 KR KR1020217034866A patent/KR20220004983A/en active Search and Examination
- 2020-03-31 CA CA3132113A patent/CA3132113A1/en active Pending
- 2020-03-31 AU AU2020254126A patent/AU2020254126A1/en active Pending
- 2020-03-31 CN CN202080036908.1A patent/CN113840616A/en active Pending
- 2020-03-31 EP EP20782777.5A patent/EP3946391A4/en active Pending
- 2020-03-31 US US17/601,619 patent/US20220202883A1/en active Pending
- 2020-03-31 JP JP2021560473A patent/JP2022528960A/en active Pending
- 2020-03-31 WO PCT/IL2020/050389 patent/WO2020202148A1/en unknown
-
2021
- 2021-09-29 IL IL286769A patent/IL286769A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1917869A1 (en) * | 2006-09-19 | 2008-05-07 | National Starch and Chemical Investment Holding Corporation | Probiotic/non-probiotic combinations |
WO2016086205A2 (en) * | 2014-11-25 | 2016-06-02 | Epiva Biosciences, Inc. | Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome |
EP3223834A2 (en) * | 2014-11-25 | 2017-10-04 | Evelo Biosciences, Inc. | Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome |
US20160354416A1 (en) * | 2015-06-01 | 2016-12-08 | The University Of Chicago | Treatment of cancer by manipulation of commensal microflora |
Non-Patent Citations (3)
Title |
---|
SCHWABE, ROBERT F. ET AL.: "The microbiome and cancer", NATURE REVIEWS CANCER, vol. 13.11, 2013, pages 800 - 812, XP055261349 * |
See also references of EP3946391A4 * |
ZITVOGEL, LAURENCE ET AL.: "The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies", SCIENCE, vol. 359.6382, 2018, pages 1366 - 1370, XP055746988 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024028479A1 (en) * | 2022-08-05 | 2024-02-08 | Universite Catholique De Louvain | Dysosmobacter for the treatment of breast cancer |
Also Published As
Publication number | Publication date |
---|---|
CN113840616A (en) | 2021-12-24 |
AU2020254126A1 (en) | 2021-11-04 |
EP3946391A4 (en) | 2022-11-30 |
IL286769A (en) | 2021-10-31 |
KR20220004983A (en) | 2022-01-12 |
JP2022528960A (en) | 2022-06-16 |
CA3132113A1 (en) | 2020-10-08 |
EP3946391A1 (en) | 2022-02-09 |
US20220202883A1 (en) | 2022-06-30 |
IL265735A (en) | 2019-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Prebiotic-induced anti-tumor immunity attenuates tumor growth | |
US11344586B2 (en) | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment | |
TWI814739B (en) | Bacterial extracellular vesicles | |
Bashiardes et al. | The microbiome in anti-cancer therapy | |
JP2020533291A (en) | Extracellular vesicles from Prevotella | |
US20220047620A1 (en) | Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment | |
KR20220020893A (en) | secreted microbial extracellular vesicles | |
US20210283169A1 (en) | Beta-glucan methods and compositions that affect the tumor microenvironment | |
Lin et al. | The adjuvant effects of high-molecule-weight polysaccharides purified from Antrodia cinnamomea on dendritic cell function and DNA vaccines | |
Wang et al. | Mushroom β‐Glucan May Immunomodulate the Tumor‐Associated Macrophages in the Lewis Lung Carcinoma | |
Ke et al. | The anti-lung cancer activity of SEP is mediated by the activation and cytotoxicity of NK cells via TLR2/4 in vivo | |
US20220202883A1 (en) | Microbial consortium and uses thereof | |
JP2023510158A (en) | Solid dosage form containing bacteria and microbial extracellular vesicles | |
JP2023522018A (en) | Solid dosage form with improved disintegration profile | |
CN116763825A (en) | Application of inactive whole cell bacteria in tumor treatment | |
Gionchetti et al. | VSL# 3: an analysis of basic and clinical contributions in probiotic therapeutics | |
JP2024501481A (en) | Extracellular vesicle preparation | |
CN116322721A (en) | Enhancement of anti-tumor effects of immune checkpoint inhibitors by administration of ruminococcus enterica | |
US9072768B2 (en) | Composition and method for increasing effectiveness of radiation or chemotherapy | |
CN115052609A (en) | A bacterial composition for treating cancer | |
Parés Bofill | The oncomicrobiotics and the influence of the microbiota in the carcinogenesis | |
CN117062913A (en) | Extracellular vesicle preparation | |
WO2022221183A1 (en) | Fournierella extracellular vesicle preparations | |
Diamond | The Role of Irradiated Tumor-Derived Exosomes in Immune Responses to Breast Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20782777 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3132113 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021560473 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020254126 Country of ref document: AU Date of ref document: 20200331 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020782777 Country of ref document: EP Effective date: 20211102 |